Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2012 Dec 21:3–230. [Article in German] doi: 10.1007/978-3-642-12921-6_1

A

Axel M Gressner 4, Torsten Arndt 5,6
Editors: Axel M Gressner1, Torsten Arndt2,3
PMCID: PMC7123472

The content is available as a PDF (7.9 MB).

Literatur

  1. Mollison PL, Engelfriet CP. Blood transfusion in clinical medicine. London: Blackwell Scientific Publications; 1993. [Google Scholar]
  2. Müller TH, Hallensleben M, Schunter F, Blasczyk R. Molekulargenetische Blutgruppendiagnostik. Deutsches Ärzteblatt. 2001;98:B267. [Google Scholar]
  3. Mueller-Eckhardt C, Kiefel V. Transfusionsmedizin. Berlin Heidelberg New York: Springer; 2003. [Google Scholar]
  4. Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz)– TFG (2007) Bundesgesetzblatt I S. 2169
  5. Bundesärztekammer (2005) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie),Aufgestellt gemäß Transfusionsgesetz von der Bundesärztekammer im Einvernehmen mit dem Paul-Ehrlich-Institut, Gesamtnovelle 2005, Deutscher Ärzteverlag, Köln
  6. Vorstand und Wissenschaftlicher Beirat der Bundesärztekammer . Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. 3. Köln: Deutscher Ärzte-Verlag; 2003. [Google Scholar]
  7. Metaxas-Bühler M. Blutgruppen und Transfusion. Bern: Verlag Hans Huber; 1995. [Google Scholar]
  8. Mueller-Eckhardt C, Kiefel V. Transfusionsmedizin: Grundlagen – Therapie – Methodik. 3. Berlin Heidelberg New York: Springer; 2004. [Google Scholar]
  9. Klein HG, Anstee DJ (2005) Mollison’s. 11th ed. Blood Transfusion in Clinical Medicine, a revision of the 10th editition written by Mollison PL, Engelfriet CP, Contreras M. Blackwell Publishing, London
  10. Falbe J, Regitz M. Römpp Chemie Lexikon. Stuttgart New York: Thieme Verlag; 1989. [Google Scholar]
  11. Abell LL, Levy BB, Brodie BB, et al. Simplified methods for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem. 1951;195:3573–3566. [PubMed] [Google Scholar]
  12. BIPM, IEC, IFCC, ILAC, ISO, IUPAC, IUPAP, OIML . Internationales Wörterbuch der Metrologie (VIM) Deutsch-englische Fassung. Berlin: Beuth-Verlag; 2010. p. 2007. [Google Scholar]
  13. Rowley JD. Letter: A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining. Nature. 1973;243:290–293. doi: 10.1038/243290a0. [DOI] [PubMed] [Google Scholar]
  14. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl Oncogene Correlates with the Presence of a Philadelphia Chromosome in Chronic Myelocytic Leukaemia. Nature. 1983;306:277–280. doi: 10.1038/306277a0. [DOI] [PubMed] [Google Scholar]
  15. Hilgers R-D, Bauer P, Scheiber V. Einführung in die Medizinische Statistik. Berlin Heidelberg New York: Springer-Verlag; 2002. [Google Scholar]
  16. Giebelmann R. Kulturgeschichtliches zum Thujon. Toxichem Krimtech. 2001;48:43–46. [Google Scholar]
  17. Kortüm G. Kolorimetrie, Photometrie und Spektrometrie. Eine Anleitung zur Ausführung von Absorptions-, Emissions-, Fluoreszenz-, Streuungs-, Trübungs- und Reflexionsmessungen. Berlin Göttingen Heidelberg: Springer-Verlag; 1962. [Google Scholar]
  18. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) Plots: A fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–577. [PubMed] [Google Scholar]
  19. Bowman HS. Red Cell Preservation in Citrate-Phosphate- Dextrose and Acid-Citrate Dextrose. Transfusion. 1963;3:364–367. doi: 10.1111/j.1537-2995.1963.tb04658.x. [DOI] [PubMed] [Google Scholar]
  20. Högman C F, Akerblom O, Hedlund K, Rosen I, Wiklund L. Red cell suspensions in SAGM medium. Vox Sang. 1983;45:217–223. doi: 10.1111/j.1423-0410.1983.tb01907.x. [DOI] [PubMed] [Google Scholar]
  21. Ferguson RA, Goldberg DM. Genetic markers of alcohol abuse. Clin Chim Acta. 1997;257:199–250. doi: 10.1016/S0009-8981(96)06444-3. [DOI] [PubMed] [Google Scholar]
  22. Gressner AM, Gressner OA. Alkoholabusus – Mittels Ethanol- abhängiger Metabolite erkennen und kontrollieren. Med Welt. 2006;57:262–270. [Google Scholar]
  23. Korri UM, Nuutinen H, Salaspuro M. Increased Blood Acetate: A New Laboratory Marker of Alcoholism and Heavy Drinking. Alcoholism: Clin Exp Res. 1985;9:468–471. doi: 10.1111/j.1530-0277.1985.tb05585.x. [DOI] [PubMed] [Google Scholar]
  24. Gressner AM, Gressner OA. Alkoholsabusus-mittels Ethanolabhängiger Metabolite erkennen und kontrollieren. Med Welt. 2006;57:262–270. [Google Scholar]
  25. Kruse-Jarres JD, Reinauer H, Witt I. 3. In: Greiling H, Gressner AM, editors. Lehrbuch der Klinischen Chemie und Pathobiochemie. Stuttgart New York: Schattauer Verlag; 1995. [Google Scholar]
  26. Löffler G, Petrides PE. Biochemie und Pathobiochemie. 5. Berlin Heidelberg New York: Springer-Verlag; 1997. [Google Scholar]
  27. Friedman S, Fraenkel G. Reversible Enzymatic Acetylation of Carnitine. Arch Biochem Biophys. 1955;51:491–501. doi: 10.1016/0003-9861(55)90515-4. [DOI] [PubMed] [Google Scholar]
  28. Gürtler AK, Löster H. Carnitin und seine Bedeutung bei der Pathogenese und Therapie von Herz- und Kreislauferkrankungen. Bochum: Ponte Press; 1996. [Google Scholar]
  29. Hilgers R-D, Bauer P, Scheiber V. Einführung in die Medizinische Statistik. Berlin Heidelberg New York: Springer-Verlag; 2002. [Google Scholar]
  30. Kurtzman NA. Renal Tubular Acidosis Syndromes. Southern Medical J. 2000;93:1042–1052. [PubMed] [Google Scholar]
  31. Swenson ER. Metabolic Acidosis. Respiratory Care. 2001;46:342–353. [PubMed] [Google Scholar]
  32. Epstein SK, Singh N. Respiratory Acidosis. Respiratory Care. 2001;46(4):366–383. [PubMed] [Google Scholar]
  33. Mollison PL, Engelfriet CP. Blood transfusion in clinical medicine. London: Blackwell Scientific Publications; 1993. [Google Scholar]
  34. Mueller-Eckhardt C, Kiefel V. Transfusionsmedizin. Berlin Heidelberg New York: Springer; 2003. [Google Scholar]
  35. Oelkers W. Dose-Response Aspects in the Clinical Assessment of the Hypothalamo-Pituitary-Adrenal Axis, and the Low-Dose Adrenocorticotropin Test. Eur J Endocrin. 1996;135:27–33. doi: 10.1530/eje.0.1350027. [DOI] [PubMed] [Google Scholar]
  36. Schulze A, Lindner M, Kohlmueller D, et al. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics. 2003;111:1399–1406. doi: 10.1542/peds.111.6.1399. [DOI] [PubMed] [Google Scholar]
  37. Addis T. The Number of Formed Elements in the Urinary Sediment of Normal Individuals. J Clin Invest. 1926;2:409–421. doi: 10.1172/JCI100055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Falbe J, Regitz M. Römpp Chemie Lexikon. Stuttgart New York: Georg Thieme Verlag; 1989. [Google Scholar]
  39. Kuhara T. Diagnosis and monitoring of inborn errors of metabolism using urease-pretreatment of urine, isotope dilution, and gas chromatography mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;781:497–517. doi: 10.1016/S1570-0232(02)00670-0. [DOI] [PubMed] [Google Scholar]
  40. Apasov SG, Blackburn MR, Kellems RE, et al. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signalling. J Clin Invest. 2001;108:131–141. doi: 10.1172/JCI10360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine phosphorylase deficiency. In: Scriver CR, Beaudet AL, al Sly WS et, editors. The molecular and metabolic basis of inherited disease. NewYork: McGraw-Hill; 1995. pp. 1725–1768. [Google Scholar]
  42. Carlucci F, Tabucchi A, Aiuti A, et al. Capillary electrophoresis in diagnosis and monitoring of adenosine deaminase deficiency. Clin Chem. 2003;49:1830–1838. doi: 10.1373/clinchem.2003.021576. [DOI] [PubMed] [Google Scholar]
  43. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost. 2008;99:466–472. doi: 10.1160/TH07-11-0673. [DOI] [PubMed] [Google Scholar]
  44. Langley JM. Adenoviruses. Pediatr Rev. 2005;26(7):244–249. doi: 10.1542/pir.26-7-244. [DOI] [PubMed] [Google Scholar]
  45. Handermann M. In: Adenoviren. 3. Darai G, Handermann M, Sonntag HG, Tidona CA, Zöller L, editors. Berlin New York S: Springer-Verlag, Heidelberg; 2009. pp. 6–11. [Google Scholar]
  46. Hoffman JA. Adenovirus infections in solid organ transplant recipients. Curr Opin Organ Transplant. 2009;14(6):625–633. doi: 10.1097/MOT.0b013e3283324e1b. [DOI] [PubMed] [Google Scholar]
  47. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metast Rev. 1999;18:345–357. doi: 10.1023/A:1006304806799. [DOI] [PubMed] [Google Scholar]
  48. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem. 2004;50:1511–1525. doi: 10.1373/clinchem.2004.032482. [DOI] [PubMed] [Google Scholar]
  49. Meier U, Gressner M. Endocrine Regulation of Energy Metabolism: Review of Pathobiochemical and Clinical Chemical Aspects of Leptin, Ghrelin, Adiponectin, and Resistin. Clin Chem. 2004;50:1511–1525. doi: 10.1373/clinchem.2004.032482. [DOI] [PubMed] [Google Scholar]
  50. Talbot JA, Kane JW, White A. Analytical and clinical aspects of adrenocorticotropin determinations. Ann Clin Biochem. 2003;40:453–471. doi: 10.1258/000456303322326371. [DOI] [PubMed] [Google Scholar]
  51. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocrine Reviews. 2000;21:138–167. doi: 10.1210/er.21.2.138. [DOI] [PubMed] [Google Scholar]
  52. Cuttitta F, Martinez A. Adrenomedullin. The Netherlands: IOS Press; 1997. [Google Scholar]
  53. Latscha HP, Linti GW, Klein HA. Analytische Chemie. Berlin Heidelberg NewYork: Springer-Verlag; 2004. [Google Scholar]
  54. American Association of Blood Banks (1999) Technical Manual 13th edition, S. Karger, Basel
  55. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223–234. doi: 10.1146/annurev.med.46.1.223. [DOI] [PubMed] [Google Scholar]
  56. Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia. 2001;44:129–146. doi: 10.1007/s001250051591. [DOI] [PubMed] [Google Scholar]
  57. Löffler G, Petrides PE. Biochemie und Pathobiochemie. Heidelberg Berlin New York: Springer; 1997. [Google Scholar]
  58. Unger KK (Hrsg) (1989) Handbuch der HPLC. Teil 1 Leitfaden für Anfänger und Praktiker. GIT Verlag, Darmstadt
  59. The MERCK Index (2006) 15. Aufl. MERCK Co., Inc. Whitehouse Station, NJ, USA
  60. Shimura K, Kasai K. Affinophoresis in two-dimensional agarose gel electrophoresis: specific separation of biomolecules by a moving affinity ligand. Anal Biochem. 1987;116:200–206. doi: 10.1016/0003-2697(87)90672-5. [DOI] [PubMed] [Google Scholar]
  61. Ogden RC, Adams DA. Electrophoresis in agarose and acrylamide gels. Meth Enzymol. 1987;152:61–87. doi: 10.1016/0076-6879(87)52011-0. [DOI] [PubMed] [Google Scholar]
  62. Le Carrer D (1994) Elektrophorese & Immunfixation von Proteinen. Die Interpretation von Versuchsergebnissen mit zahlreichen Trennbeispielen. SA Sebia, Paris
  63. Martin R. Elektrophorese von Nucleinsäuren. Heidelberg: Spektrum Akademischer Verlag; 1996. [Google Scholar]
  64. Mueller-Eckhardt C, Kiefel V, Grundlagen –, Methodik –. Transfusionsmedizin:Grundlagen – Therapie – Methodik. Berlin Heidelberg New York: Springer; 2004. [Google Scholar]
  65. Eckstein R. Immunhämatologie und Transfusionsmedizin. Stuttgart: Fischer; 2005. [Google Scholar]
  66. Berzofsky JA, Epstein SL, Berkower IJ. Antigenantibody interactions and monoclonal antibodies. In: Paul WA, editor. undamental Immunology. 2nd. New York: Raven Press; 1989. [Google Scholar]
  67. Kiani C, Chen, Wu L. Structure and function of aggrecan. Cell Res. 2002;12:19–32. doi: 10.1038/sj.cr.7290106. [DOI] [PubMed] [Google Scholar]
  68. Lark MW, Bayne EK, Flanagan J, et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthrotic, and rheumatoid joints. J Clin Invest. 1997;100:93–106. doi: 10.1172/JCI119526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Fischer DC, Kolbe-Busch S, Stöcker G, et al. Development of enzyme immuno assays for keratan sulphate- and core-protein epitopes of the large aggregating proteoglycan from human articular cartilage. Eur J Clin Clin Biochem. 1994;32:285–291. doi: 10.1515/cclm.1994.32.4.285. [DOI] [PubMed] [Google Scholar]
  70. Malfait AM, Lui RQ, Ijiri K, et al. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem. 2002;277:2201–2208. doi: 10.1074/jbc.M200431200. [DOI] [PubMed] [Google Scholar]
  71. Lark MW, Bayne EK, Flanagan J, et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthrotic, and rheumatoid joints. J Clin Invest. 1997;100:93–106. doi: 10.1172/JCI119526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Moll J, Barzaghi P, Lin S, Bezakova G, Lochmuller H, Engvall E, Muller U, Ruegg MA. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature. 2001;413:302–307. doi: 10.1038/35095054. [DOI] [PubMed] [Google Scholar]
  73. Raats CJ, Bakker MA, Hoch W, Tamboer WP, Groffen AJ, Van Den Heuvel LP, Berden JH, Van Den Born J. Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem. 1998;273:17832–17838. doi: 10.1074/jbc.273.28.17832. [DOI] [PubMed] [Google Scholar]
  74. Schütz E, Schaefer RM, Heidbreder E, et al. Effect of diuresis on urinary erythrocyte morphology in glomerulonephritis. Klin Wchschr. 1985;63:575–577. doi: 10.1007/BF01733007. [DOI] [PubMed] [Google Scholar]
  75. Köhler H, Wandel E, Brunck B. Acanthocyturia – a characteristic marker of glomerular bleeding. Kidney Int. 1991;40:115–120. doi: 10.1038/ki.1991.188. [DOI] [PubMed] [Google Scholar]
  76. DIN EN ISO/IEC 17000:2005 „Konformitätsbewertung – Begriffe und allgemeine Grundlagen“
  77. DIN EN ISO/IEC 17011:2005 „Allgemeine Anforderungen an Akkreditierungsstellen, die Konformitätsbewertungsstellen akkreditieren“
  78. Gabay C, Kushner I. Acute-Phase Proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454. doi: 10.1056/NEJM199902113400607. [DOI] [PubMed] [Google Scholar]
  79. Gressner AM, Thomas L. Aufl. In: Greiling H, Gressner AM, editors. Proteinstoffwechsel. In: Greiling H, Gressner AM (Hrsg) Lehrbuch der Klinischen Chemie und Pathobiochemie. Stuttgart: Schattauer-Verlag; 1995. pp. 194–246. [Google Scholar]
  80. Bull BS, et al. Guidelines on selection of laboratory tests for monitoring the acute phase response. J Clin Pathol. 1988;41:1203–1212. doi: 10.1136/jcp.41.11.1203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Duran M. Amino acids. In: Blau N, Duran M, Gibson KM, editors. Laboratory Guide to the Methods in Biochemical Genetics. Heidelberg: Springer; 2008. pp. 53–90. [Google Scholar]
  82. Haas RH, Parikh A, Falk MJ, et al. The in-depth evaluation of ksuspected mitochondrial disease. Mol Genet Metab. 2008;94:16–37. doi: 10.1016/j.ymgme.2007.11.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Doumas BT, Peters T. Serum and urine albumin: a progress report on their measurement and clinical significance. Clin Chim Acta. 1997;258:3–20. doi: 10.1016/S0009-8981(96)06446-7. [DOI] [PubMed] [Google Scholar]
  84. Quinlan G J, Martin G S, Evans T W. Albumin: Biochemical properties and therapeutic potential. Hepatology. 2005;41:1211–1219. doi: 10.1002/hep.20720. [DOI] [PubMed] [Google Scholar]
  85. Arroyo V. Human serum albumin: Not just a plasma volume expander. Hepatology. 2009;50:355–357. doi: 10.1002/hep.23006. [DOI] [PubMed] [Google Scholar]
  86. Hasslacher C, Wolf G, Kampe P, Ritz E. In: Praxisleitlinien der Deutschen Diabetes-Gesellschaft. Diabetische Nephropathie. 2008;3(2):S143. [Google Scholar]
  87. Hofmann W, Ehrich JHH, Guder WG, Keller F, Scherberich JE. Diagnostische Pfade bei Nierenerkrankungen. Nieren- und ochdruckkrankheiten. 2011;40:47–70. [Google Scholar]
  88. Osicka TM, Comper WD. Characterization of Immunochemically Nonreactive Urinary Albumin. Clin Chem. 2004;50:2286–2291. doi: 10.1373/clinchem.2004.039743. [DOI] [PubMed] [Google Scholar]
  89. Schena FP. Domenico Cotugno and his interest in Proteinuria. Am J Nephrol. 1994;14:325–329. doi: 10.1159/000168743. [DOI] [PubMed] [Google Scholar]
  90. Alder A. Über konstitutionell bedingte Granulationsveränderungen der Leukocyten. Dtsch Arch Klin Med. 1939;183:372–378. [Google Scholar]
  91. Löffler H, Rastetter J. Atlas der klinischen Hämatologie. Berlin Heidelberg New York: Springer-Verlag; 1999. pp. 44–46. [Google Scholar]
  92. Ali M, Rellos P, Cox TM. Hereditary fructose intolerance. J Med Genet. 1998;35:353–365. doi: 10.1136/jmg.35.5.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Hubl W, Thomas L. Renin-Angiotensin-Aldosteron- System. In: Thomas L, editor. Labor und Diagnose. 6. Frankfurt: TH-Books; 2005. pp. 1406–1424. [Google Scholar]
  94. Abdelhamid S, Blomer R, Hommel G, et al. Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study. Am J Hypertens. 2003;16:522–530. doi: 10.1016/S0895-7061(03)00858-6. [DOI] [PubMed] [Google Scholar]
  95. Perschel FH, Schemer R, Seiler L, et al. Rapid Screening Test for Primary Hyperaldosteronism: Ratio of Plasma Aldosterone to Renin Concentration Determined by Fully Automated Chemiluminescence Immunoassays. Clin Chem. 2004;50:1650–1655. doi: 10.1373/clinchem.2004.033159. [DOI] [PubMed] [Google Scholar]
  96. Schwartz GL, Chapman AB, Boerwinkle E, et al. Screening for primary aldosteronism: Implications of an increased plasma aldosterone/ renin ratio. Clin Chem. 2002;48:1919–1923. [PubMed] [Google Scholar]
  97. Huber H, Pastner D, Gabl F. Laboratoriumsdiagnose hämatologischer und immunologischer Erkrankungen. Berlin: Springer- Verlag, Berlin Heidelberg; 1972. pp. 216–218. [Google Scholar]
  98. Peters JP, van Slyke DD. Quantitative Clinical Chemistry. II. Methods. 1. Baltimore: Williams and Wilkins; 1932. [Google Scholar]
  99. Meifsner W. Ueber ein neues Pflanzenalkali (Alkaloid) J Chem Phys. 1819;XXV:377–381. [Google Scholar]
  100. Moss GP, Smith PAS, Tavernier D. Glossary of class names of organic compounds and reactivity intermediates based on structure (IUPAC Recommendations 1995) Pure & Appl Chem. 1995;67:1313. [Google Scholar]
  101. Teuscher E, Lindequist U. Biogene Gifte. Biologie – Chemie – Pharmakologie – Toxikologie. 3. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 2010. [Google Scholar]
  102. Grobe N (2009) Biosynthesis of Morphins in Mammals. Dissertation, Naturwissenschaftliche Fakultät I, Biowissenschaften, Martin-Luther- Universität Halle (http://digital.bibliothek.uni-halle.de/hs/content/titleinfo/411034;Stand:28.September2011 )
  103. Khanna A, Kurtzman NA. Metabolic Alkalosis. Respiratory Care. 2001;46:354–365. [PubMed] [Google Scholar]
  104. Foster GT, Vaziri ND, Sassoons CS. Respiratory Alkalosis. Respiratory Care. 2001;46:384–391. [PubMed] [Google Scholar]
  105. Guder WG, Narayanan S, Wisser H, Zawta B. Diagnostic Samples: From the Patient to the Laboratory. 4. Weinheim: Wiley- Blackwell; 2009. [Google Scholar]
  106. Young DS (2007) Effects of Preanalytical Variables on Clinical Laboratory Tests. 3rd edn. AACC Press, Washington DC
  107. Zintzaras E, Stefanidis I, Santos M, Vidal F. Do Alcohol-Metabolizing Enzyme Gene Polymorphisms Increase the Risk of Alcoholism and Alcoholic Liver Disease? Hepatology. 2006;43:352–361. doi: 10.1002/hep.21023. [DOI] [PubMed] [Google Scholar]
  108. Arndt T, Gressner AM, Kropf J. Labordiagnostik und Kontrolle des Alkoholabusus – ein Plädoyer für Carbohydrate- Deficient-Transferrin (CDT) medwelt. 1994;45:247–257. [Google Scholar]
  109. Arndt T. Biomarker des Alkoholkonsums – Eine Übersicht. Toxichem Krimtech. 2011;78:419–430. [Google Scholar]
  110. Thomas L (Hrsg) (2008) Labor und Diagnose. 7. Aufl. Frankfurt/Main, S 1120f
  111. Eckstein R. mmunhämatologie und Transfusionsmedizin. München: Urban & Fischer; 2005. [Google Scholar]
  112. Mueller-Eckhardt C, Kiefel V. Transfusionsmedizin. New York: Springer, Berlin Heidelberg; 2003. [Google Scholar]
  113. Eckstein R. Immunhämatologie und Transfusionsmedizin. München Mueller: Urban & Fischer; 2005. [Google Scholar]
  114. Eckhardt C, Kiefel V. Transfusionsmedizin. New York: Springer, Berlin Heidelberg; 2003. [Google Scholar]
  115. Bremer HJ, Duran M, Kamerling JP, et al. Disturbances of Aminoacid Metabolism: Clinical Chemistry and Diagnosis. Munich and Baltimore: Urban & Schwarzenberg; 1981. [Google Scholar]
  116. Duran M. Amino acids. In: Blau N, Duran M, Gibson KM, editors. Laboratory Guide to the Methods in Biochemical Genetics. New York: Springer, Heidelberg Berlin; 2008. pp. 53–90. [Google Scholar]
  117. Hafner L, Hoff P. Genetik. Hannover Dortmund Darmstadt Berlin: Hermann Schroedel Verlag; 1977. [Google Scholar]
  118. Hallmann L, Burkhardt F. Klinische Mikrobiologie. Stuttgart New York: Georg Thieme Verlag; 1974. [Google Scholar]
  119. Hilgers RD, Bauer P, Scheiber V. Einführung in die Medizinische Statistik. Berlin Heidelberg New York: Springer-Verlag; 2002. [Google Scholar]
  120. Elsenhans B. In: Aluminium. Biesalski HK, Köhrle J, Schümann K, editors. Stuttgart New York: Georg Thieme Verlag; 2002. pp. 227–231. [Google Scholar]
  121. Kazazian HH. Mobile Elements: Drivers of Genome Evolution. Science. 2004;303:1626–1632. doi: 10.1126/science.1089670. [DOI] [PubMed] [Google Scholar]
  122. Iizuka M, Mashiyama S, Oshimura M, et al. Cloning and Polymerase Chain Reation-Single-Strand Conformation Polymorphism Analysis of Anonimous Alu Repeats on Chromosome 11. Genomics. 1992;12:139–146. doi: 10.1016/0888-7543(92)90416-P. [DOI] [PubMed] [Google Scholar]
  123. Löffler G, Petrides PE. Biochemie und Pathobiochemie. Berlin Heidelberg New York: Springer-Verlag; 1997. [Google Scholar]
  124. Degel F. Poisonous mushrooms. In: Külpmann WR, editor. Clincial toxicological analysis. Weinheim: Wiley-VCH; 2009. pp. 809–823. [Google Scholar]
  125. Westermeier R. Electrophoresis in Practice. Weinheim: Wiley-VCH; 2004. [Google Scholar]
  126. Ludewig R. Akute Vergiftungen. Wiss. Stuttgart: Verlagsgesellschaft; 1999. pp. 100–102. [Google Scholar]
  127. Bremer HJ, Duran M, Kamerling JP, et al. Disturbances of Aminoacid Metabolism: Clinical Chemistry and Diagnosis. Munich and Baltimore: Urban & Schwarzenberg; 1981. [Google Scholar]
  128. Sewell AC, Herwig J, Böhles H, et al. Normal kynurenine metabolism in 2-oxoadipic aciduria. J Inher Metab Dis. 1999;22:949–950. doi: 10.1023/A:1005672314435. [DOI] [PubMed] [Google Scholar]
  129. Bremer HJ, Duran M, Kamerling JP, et al. Disturbances of Aminoacid Metabolism: Clinical Chemistry and Diagnosis. Munich and Baltimore: Urban & Schwarzenberg; 1981. [Google Scholar]
  130. Jaeken J, Jakobs C, Wevers R. Disorders of Neurotransmission. In: Fernandes J, Saudubray J-M, van den Berghe G, editors. Inborn Metabolic Diseases: Diagnosis and Treatment. 3. Berlin Heidelberg New York: Springer- Verlag; 2000. pp. 301–311. [Google Scholar]
  131. Roberts E, Frankel S. Gamma-aminobutyric acid in brain: its formation from glutamic acid. J Biol Chem. 1950;187:55–63. [PubMed] [Google Scholar]
  132. Bremer HJ, Duran M, Kamerling JP, et al. Disturbances of Aminoacid Metabolism: Clinical Chemistry and Diagnosis. Munich and Baltimore: Urban & Schwarzenberg; 1981. [Google Scholar]
  133. Mauzerall D, Granick S. The Occurrence and Determination of δ-Aminolevulinic Acid and Porphobilinogen in Urine. J Biol Chem. 1956;219:435–446. [PubMed] [Google Scholar]
  134. Doss MO. 5. In: Thomas L, editor. Labor und Diagnose. Frankfurt/Main: TH Books Verlagsgesellschaft mbH; 2000. pp. 458–474. [Google Scholar]
  135. Bishop DF, Desnick RJ. Assays of the Heme Biosynthetic Enzymes. Enzyme. 1982;28:2–3. [PubMed] [Google Scholar]
  136. Doss MO. Porphyrie. In: Thomas L, editor. Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die Medizinische Diagnostik. Frankfurt/Main: TH-Books; 2000. pp. 458–474. [Google Scholar]
  137. Bickers DR, Frank J. In: Dermatology in General Medicine. 6. Freedberg IM, Eisen AZ, et Wolff, editors. New York: McGraw Hill; 2003. pp. 1435–1466. [Google Scholar]
  138. Bishop DF, Desnick RJ. Assays of the Heme Biosynthetic Enzymes. Enzyme. 1982;28(2-3):89–232. [PubMed] [Google Scholar]
  139. Doss MO. In: Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die Medizinische Diagnostik. Thomas L, editor. Frankfurt/Main: TH-Books; 2000. pp. 458–474. [Google Scholar]
  140. Bickers DR, Frank J. In: Dermatology in General Medicine. 6th. Freedberg IM, et AZ, Wolff, editors. New York: McGraw Hill; 2003. pp. 1435–1466. [Google Scholar]
  141. Merkel C, Bolognesi M, Bellon S, et al. Aminopyrine Breath Test in the Prognostic Evaluation of Patients with Cirrhosis. Gut. 1992;33:836–842. doi: 10.1136/gut.33.6.836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Chernoff R. Protein and older adults. J Am Coll Clin Nutr. 2004;23:627S. doi: 10.1080/07315724.2004.10719434. [DOI] [PubMed] [Google Scholar]
  143. Duran M. Amino acids. In: Blau N, Duran M, Gibson KM, editors. Laboratory Guide to the Methods in Biochemical Genetics. Berlin Heidelberg New York: Springer; 2008. pp. 53–90. [Google Scholar]
  144. Moore S, Spackman DS, Stein WH. Automatic recording device for use in the chromatography of amino acids. Fed Proc. 1958;17:1107–1115. [PubMed] [Google Scholar]
  145. Schulze A, Lindner M, Kohlmueller D, Olgemoeller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of  etabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics. 2003;111:1399–1406. doi: 10.1542/peds.111.6.1399. [DOI] [PubMed] [Google Scholar]
  146. Clemens JD, Herrick MV, Singer FR, et al. Evidence that serum NTx (collagen type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem. 1997;43:2058–2063. [PubMed] [Google Scholar]
  147. Hanson DA, Eyre DR. Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem. 1996;271:26508–26516. doi: 10.1074/jbc.271.26.15307. [DOI] [PubMed] [Google Scholar]
  148. Ju H-SJ, Leung S, Brown B, et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem. 1997;43:1570–1576. [PubMed] [Google Scholar]
  149. Kanda S, Sudo K, Kanno T. A specific kinetic assay for tripeptide aminopeptidase in serum. Clin Chem. 1984;30:843–846. [PubMed] [Google Scholar]
  150. König H, Schmoldt M. Antidysrhythmic agents. In: Külpmann WR, editor. Clincial toxicological analysis. Weinheim: Wiley-VCH; 2009. pp. 271–285. [Google Scholar]
  151. Bachmann C. Mechanisms of Hyperammonemia. Clin Chem Lab Med. 2002;40:653–662. doi: 10.1515/CCLM.2002.112. [DOI] [PubMed] [Google Scholar]
  152. Häberle J, Koch HG. Hyperammonämie: Ursachen, Diagnostik, Therapie. Dtsch Med Wochenschr. 2004;129:1381–1384. doi: 10.1055/s-2004-826878. [DOI] [PubMed] [Google Scholar]
  153. Da Fonseca-Wollheim Direkte Plasmaammoniakbestimmung ohne Enteiweißung. J Clin Chem Clin Biochem. 1973;11:426–431. [PubMed] [Google Scholar]
  154. Castell DO. The ammonia tolerance test: An index of portal hypertension. Gastroenterology. 1965;49:539–543. [PubMed] [Google Scholar]
  155. Thomas L. Labor und Diagnose. Frankfurt/Main: TH-Books; 2005. [Google Scholar]
  156. Greiling H, Gressner AM. Lehrbuch der Klinischen Chemie und Pathobiochemie. New York: Schattauer Verlag, Stuttgart; 1994. [Google Scholar]
  157. Näser K-H, Peschel G. Physikalisch-chemische Meßmethoden. Leipzig: Deutscher Verlag für Grundstoffindustrie; 1986. [Google Scholar]
  158. Latscha HP, Linti GW, Klein HA. Analytische Chemie. New York: Springer-Verlag, Berlin Heidelberg; 2004. [Google Scholar]
  159. Allen RC, Graves, Budowle G. Polymerase Chain Reaction Amplification Products Separated on Rehydratable Polyacrylamide Gels and Stained with Silver. Biotechniques. 1989;7:736–744. doi: 10.1038/nbt0789-736. [DOI] [PubMed] [Google Scholar]
  160. Budowle B, Chakraborty R, Giusti AM, et al. Analysis of the VNTR Locus D1S80 by the PCR Followed by High-Resolution PAGE. Am J Hum Genet. 1991;48:841–855. [PMC free article] [PubMed] [Google Scholar]
  161. Käferstein H, Sticht G. In: Amphetamines. Külpmann WR, editor. Weinheim: Wiley-VCH; 2009. pp. 463–470. [Google Scholar]
  162. Zaske D, Cerra FB, Koontz FP. In: A textbook for the clinical application of therapeutic drug monitoring. Taylor WJ, Diers Caviness MH, editors. Irving: Abbott; 1986. [Google Scholar]
  163. Clavé P, Guillaumes S, Blanco I, et al. Amylase, Lipase, Pancreatic Isoamylase, and hospholipase A in Diagnosis of Acute Pancreatitis. Clin Chem. 1995;41:1129–1134. [PubMed] [Google Scholar]
  164. Junge W, Wortmann W, Wilke B, et al. Development and evaluation of assays for the determination of total and pancreatic amylase at 37 °C according to the principle recommended by the IFCC. Clin Biochem. 2001;34:607–615. doi: 10.1016/S0009-9120(01)00278-8. [DOI] [PubMed] [Google Scholar]
  165. Hull RL, Westermark GT, Westermark P, et al. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab. 2004;89:3629–3643. doi: 10.1210/jc.2004-0405. [DOI] [PubMed] [Google Scholar]
  166. Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. Rev Endocr Metab Disord. 2003;4:95–102. doi: 10.1023/A:1021831621210. [DOI] [PubMed] [Google Scholar]
  167. Schönland SO. Fortschritte in der Diagnostik und Therapie der Amyloidosen. Dtsch Arztebl. 2006;103:A2237. [Google Scholar]
  168. Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–2371. doi: 10.1056/NEJMoa070265. [DOI] [PubMed] [Google Scholar]
  169. Fagan AM, Shaw LM, Xiong Cet. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol. 2011;68:1137–1144. doi: 10.1001/archneurol.2011.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Kim J, Holtzman DM. Prion-like behavior of amyloid-β. Science. 2010;330:918–919. doi: 10.1126/science.1198314. [DOI] [PubMed] [Google Scholar]
  171. Lahiri DK, Maloney B. Beyond the signaling effect role of amyloid-β42 on the processing of APP, and its clinical implications. Exp Neurol. 2010;225:51–54. doi: 10.1016/j.expneurol.2010.04.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Rösler N, Wichart I, Jellinger KA. Aktuelle klinisch-neurochemische Diagnostik der Alzheimer-Krankheit. J Lab Med. 2002;26:139–148. doi: 10.1046/j.1439-0477.2002.02031.x. [DOI] [Google Scholar]
  173. Greiling H, Gressner AM (Hrsg) (1995) Lehrbuch der Klinischen Chemie und Pathobiochemie. Schattauer Verlag, Stuttgart New York
  174. DIN-Norm EN ISO/IEC 17025
  175. GTFCh Richtlinie der GTFCh zur Qualitätssicherung bei forensisch-toxikologischen Untersuchungen. Toxichem Krimtech. 2009;76:142–176. [Google Scholar]
  176. TIAFT (2001) Systematic Toxicological Analysis: Laboratory Guidelines. TIAFT Bulletin XXXI Nr. 4:23-26 oder http://www.tiaft.org/about/sta_laboratory.php,geprüft16.08.2011
  177. Kingston HM, Kingston ML. Nomenclature in laboratory robotics and automation. Pure & Appl Chem. 1994;66:609–630. doi: 10.1351/pac199466030609. [DOI] [Google Scholar]
  178. Haeckel R. Rationalisierung quantitativer Analysenverfahren. In: Greiling H, Gressner AM, editors. Lehrbuch der Klinischen Chemie und Pathobiochemie. Stuttgart New York: Schattauer Verlag; 1995. [Google Scholar]
  179. Skeggs LT. An automatic method for colorimetric analysis. Am J Clin Path. 1957;28:311–322. doi: 10.1093/ajcp/28.3_ts.311. [DOI] [PubMed] [Google Scholar]
  180. EN 12286 (1998)
  181. Haeckel R, Fischer G, Fischer M, et al. Vorschläge zur Definition von Zeitbegriffen. Dt Ges Klin Chem Mitteilungen. 1984;14:187–192. [Google Scholar]
  182. Richtlinie der Bundesärztekammer zur Qualitätssicherung quantitativer laboratoriumsmedizinischer Untersuchungen (2008) Dt Ärzteblatt 105:A3417–A355
  183. Stamm D, Büttner J. Klinisch-chemische Analytik. In: Greiling H, Gressner AM, editors. Lehrbuch der Klinischen Chemie und Pathobiochemie. Stuttgart: Schattauer Verlag; 1995. pp. 6–36. [Google Scholar]
  184. Miller KK, Rosner W, Lee H, et al. Measurement of Free Testosterone in Normal Women and Women with Androgen Deficiency: Comparison of Methods. J Clin Endocrinol Metab. 2004;89:525–533. doi: 10.1210/jc.2003-030680. [DOI] [PubMed] [Google Scholar]
  185. Miller KK, Rosner W, Lee H, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab. 2004;89:525–533. doi: 10.1210/jc.2003-030680. [DOI] [PubMed] [Google Scholar]
  186. Castracane VD, et al. Androgen parameters in hirsute and normal female patients: is there a role for the free androgen index (FAI)? Clin Chem. 1999;45:A80. [Google Scholar]
  187. Burger HG. Androgen Production in Women. Fertil Steril. 2002;77:3–5. doi: 10.1016/S0015-0282(02)02985-0. [DOI] [PubMed] [Google Scholar]
  188. Cavallo A, Corn C, Bryan GT, et al. The Use of Plasma Androstenedione in Monitoring Therapy of Patients with Congenital Adrenal Hyperplasia. J Pediatr. 1979;95:33–37. doi: 10.1016/s0022-3476(79)80078-5. [DOI] [PubMed] [Google Scholar]
  189. Gladtke E, von Hattingberg HM. Pharmakokinetik. Berlin Heidelberg New York: Springer-Verlag; 1973. [Google Scholar]
  190. Bunting PS, Szalai JP, Katic M. Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis. Clin Biochem. 1987;20:213–219. doi: 10.1016/S0009-9120(87)80123-6. [DOI] [PubMed] [Google Scholar]
  191. Arbustini E, Grasso M, Fasani R, Klersy C, Diegoli M, Porcu E, Banchieri N, Fortina P, Danesino C, Specchia G. Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Brit Heart J. 1995;74:584–591. doi: 10.1136/hrt.74.6.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  192. Mattei M-G, Hubert C, Alhenc-Gelas F, Roeckel N, Corvol P, Soubrier F. Angiotensin-I converting enzyme gene is on chromosome 17. Cytogenet Cell Genet. 1989;51:1041. [Google Scholar]
  193. Morimatsu H, Rocktaschel J, Bellomo R, et al. Comparison of Point-of-Care versus Central Laboratory Measurement of Electrolyte Concentrations on Calculations of the Anion Gap and the Strong Ion Difference. Anesthesiology. 2003;98:1077–1084. doi: 10.1097/00000542-200305000-00009. [DOI] [PubMed] [Google Scholar]
  194. Koeppen KM, Heller S. Differenzialblutbild (panoptische Färbung) In: Boll I, Heller S, editors. Praktische Blutzelldiagnostik. Berlin Heidelberg New York: Springer-Verlag; 1991. p. 170. [Google Scholar]
  195. Hilgers R-D, Bauer P, Scheiber V. Einführung in die Medizinische Statistik. Berlin Heidelberg New York: Springer-Verlag; 2002. [Google Scholar]
  196. Falbe J, Regitz M. Römpp Chemie Lexikon. Stuttgart New York: Thieme Verlag; 1990. [Google Scholar]
  197. Bremer HJ, Duran M, Kamerling JP et al (1981) Disturbances of Aminoacid Metabolism: Clinical Chemistry and Diagnosis, Urban & Schwarzenberg, Munich and Baltimore
  198. Gabay C, Kushner I. Acute-Phase Proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454. doi: 10.1056/NEJM199902113400607. [DOI] [PubMed] [Google Scholar]
  199. Genné D, Siegrist H. Vom Antibiogramm zur Wahl eines Antibiotikums. Schweiz Med Forum. 2003;20:464–468. [Google Scholar]
  200. Mutschler E (2001) Arzneimittelwirkungen. Lehrbuch der Pharmakologie und Toxikologie. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart
  201. www.mikrobio.med.tu-muenchen.de/diagnose/nachweis/immunreaktion3.html
  202. Zhang S, Janciauskiene S. Multifunctional capability of proteins: α1-antichymotrypsin and the correlation with Alzheimer’s disease. J Alzheimer’s Disease. 2002;4:115–122. doi: 10.3233/jad-2002-4206. [DOI] [PubMed] [Google Scholar]
  203. Degel F, Birkhahn HJ, Demme U, et al. Neuroleptic drugs and antidepressants. In: Külpmann WR, et al., editors. Clincial toxicological analysis. Weinheim: Wiley; 2009. pp. 393–453. [Google Scholar]
  204. Hallbach J, Rentsch K. In: Antidiabetics. Külpmann WR, editor. Weinheim: Wiley; 2009. pp. 613–621. [Google Scholar]
  205. Robertson GL. The Use of Vasopressin Assays in Physiology and Pathophysiology. Semin Nephrol. 1994;14:368–383. [PubMed] [Google Scholar]
  206. Robertson GL. Antidiuretic Hormone. Normal and Disordered Function. Endocrinol Metab Clin North Am. 2001;30:671–694. doi: 10.1016/S0889-8529(05)70207-3. [DOI] [PubMed] [Google Scholar]
  207. Bundesärztekammer (2005) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie), Aufgestellt gemäß Transfusionsgesetz von der Bundesärztekammer im Einvernehmen mit dem Paul-Ehrlich- Institut, Gesamtnovelle 2005, Deutscher Ärzteverlag, Köln
  208. Cruise JM, Lewis RE. Atlas of Immunology. Berlin Heidelberg New York: Springer-Verlag; 1999. [Google Scholar]
  209. www.mikrobio.med.tu-muenchen.de/diagnose/ nachweis/ immunreaktion3.html
  210. Klein J, Horejsi V. Immunology. 2nd. Oxford: Blackwell Sciences; 1997. pp. 466–468. [Google Scholar]
  211. Thomas L. Labor und Diagnose. 6. Frankfurt/Main: THBook; 2005. p. 1918f. [Google Scholar]
  212. Heidelberger M, Kendall, ( FE. A quantitative theory of the precipitin reaction: III. The reaction between crystalline egg albumin and its homologous antibody. J Exp Med. 1935;62:697–720. doi: 10.1084/jem.62.5.697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  213. Coombs RRA, Mourant AE, Race RR. A new test for the detection of weak and „incomplete Rh agglutinins“. Br J Exp Pathol. 1945;26:255–266. [PMC free article] [PubMed] [Google Scholar]
  214. Bihoreau N, et al. Copper-atom identification in the active and inactive forms of plasma-derivided FVIII and recombinant FVIII-delta II. Eur Biochem. 1994;222:41–48. doi: 10.1111/j.1432-1033.1994.tb18839.x. [DOI] [PubMed] [Google Scholar]
  215. Rosenblum WI. In vitro measurements of the effects of anticoagulants on the flow properties of blood: the relationship of these effects to red cell shrinkage. Blood. 1968;31:234–241. [PubMed] [Google Scholar]
  216. CLSI Document H1-A6 (2010) Tubes and additives for venous and capillary blood specimen collection; approved standard EN/DIN 14820 (2004) Gefäße zur einmaligen Verwendung für die venöse Blutabnahme beim Menschen. Beuth-Verlag, Berlin
  217. Immunglobulin-Subklassen
  218. Köhler G, Milstein C. Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature. 1975;256:495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  219. Thomas L. Labor und Diagnose. 6. Frankfurt/Main: THBooks; 2005. p. 1121. [Google Scholar]
  220. Rose C, Dähnrich C, Probst C, Komorowski L, Stöcker W, Schlumberger W, Zillikens D (2008) Anti-GAF(3X)-ELISA (IgG) in combination with Anti-tTG-ELISA (IgA) identifies 100 % of celiac disease patients with dermatitis herpetiformis Duhring and positive intestinal biopsy (Marsh III). 6th International Congress on Autoimmunity in Porto, Portugal
  221. Prause C, Ritter M, Probst C, Dähnrich C, Schlumberger W, Komorowski L, Lieske R, Richter T, Hauer AC, Stern M, Uhlig H, Laas M, Zimmer KP, Mothes T. Antibodies against deamidated gliadin as new and accurate biomarkers of childhood coeliac disease. J Pediatr Gastroenterol Nutr. 2009;49:52–58. doi: 10.1097/MPG.0b013e318195dae3. [DOI] [PubMed] [Google Scholar]
  222. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep. 2003;2:148–157. [PubMed] [Google Scholar]
  223. Kivisakk P, Alm GV, Fredrikson S, et al. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol. 2000;7:27–34. doi: 10.1046/j.1468-1331.2000.00002.x. [DOI] [PubMed] [Google Scholar]
  224. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ. 1988;297:1105–1106. doi: 10.1136/bmj.297.6656.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  225. Teegen B, Müller-Kunert E, Zerbe B, Dähnrich C, Groeury M, Humbel RL, Schlumberger W, Stöcker W. Prevalence of antibodies against Saccharomyces cerevisiae in the diagnosis of chronic-inflammatory bowel disease. J Lab Med. 2000;24:494. [Google Scholar]
  226. Damoiseaux JG, Bouten B, Linders AM, Austen J, Roozendaal C, Russel MG, Forget PP, Tervaert JW. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease. High prevalence in patients with celiac disease J Clin Immunol. 2002;22(5):281–288. doi: 10.1023/a:1019926121972. [DOI] [PubMed] [Google Scholar]
  227. Lütticken R. Streptococcae. In: Burkhardt F, editor. Mikrobiologische Diagnostik. Stuttgart: Georg Thieme Verlag; 1992. pp. 51–62. [Google Scholar]
  228. Mueller-Eckhardt C, Kiefel V. Transfusionsmedizin:Grundlagen – Therapie – Methodik. 3. Berlin: Springer; 2004. [Google Scholar]
  229. Eckstein R. Immunhämatologie und Transfusionsmedizin. 5. Stuttgart: Gustav Fischer; 2005. [Google Scholar]
  230. Salama A, Mueller-Eckhardt C. Nachweis von erythrozytären Antigenen und Antikörpern. In: Mueller-Eckhardt C, editor. Transfusionsmedizin. Berlin Heidelberg New York: Springer; 1996. pp. 587–596. [Google Scholar]
  231. Mueller-Eckhardt C, Kiefel V. Transfusionsmedizin: Grundlagen – Therapie – Methodik. 3. Berlin: Springer; 2004. [Google Scholar]
  232. Eckstein R. Immunhämatologie und Transfusionsmedizin. 5. Stuttgart: Gustav Fischer; 2005. [Google Scholar]
  233. Salama A, Mueller-Eckhardt C. Nachweis von erythrozytären Antigenen und Antikörpern. In: Mueller-Eckhardt C, editor. Transfusionsmedizin. Berlin Heidelberg New York: Springer; 1996. pp. 587–596. [Google Scholar]
  234. Mueller-Eckhardt C, Kiefel V. Transfusionsmedizin: Grundlagen – Therapie – Methodik. 3. Berlin: Springer; 2004. [Google Scholar]
  235. Eckstein R. Immunhämatologie und Transfusionsmedizin. 5. Stuttgart: Gustav Fischer; 2005. [Google Scholar]
  236. American Association of Blood Banks (1999) Technical Manual 13th ed. S. Karger, Basel
  237. Bencze K. In: Antimony. Seiler HG, Sigel A, Sigel H, editors. New York Basel Hong Kong: Marcel Dekker; 1994. pp. 227–236. [Google Scholar]
  238. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction. 2002;124(5):601–609. doi: 10.1530/rep.0.1240601. [DOI] [PubMed] [Google Scholar]
  239. Gnoth C, Schuring AN, Friol K, Tigges J, Mallmann P, Godehardt E. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod. 2008;23(6):1359–1365. doi: 10.1093/humrep/den108. [DOI] [PubMed] [Google Scholar]
  240. Broekmans FJ, Visser JA, Laven JS, Broer SL, Themmen AP, Fauser BC. Anti-Müllerian hormone and ovarian dysfunction. Trends Endocrinol Metab. 2008;19(9):340–347. doi: 10.1016/j.tem.2008.08.002. [DOI] [PubMed] [Google Scholar]
  241. Miller NJ, Rice-Evans C, et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature infants. Clin Sci. 1993;84:407–412. doi: 10.1042/cs0840407. [DOI] [PubMed] [Google Scholar]
  242. Coughlin PB. Antiplasmin. The forgotten serpin. 2005;272:4852–4857. doi: 10.1111/j.1742-4658.2005.04881.x. [DOI] [PubMed] [Google Scholar]
  243. Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2012;55:1019–1029. doi: 10.1002/hep.24752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  244. Grieco A, Castellano R, Matera A. Antipyrine clearance in chronic und neoplastic liver diseases: a study of 518 patients. J Gastroenterol Hepatol. 1998;13:460–466. doi: 10.1111/j.1440-1746.1998.tb00668.x. [DOI] [PubMed] [Google Scholar]
  245. Bachellerie JP, Michot B, Nicoloso M, et al. Antisense snoRNAs: A Family of Nucleolar RNAs with Long Complementarities to rRNA. Trends Biochem Sci. 1995;20:261–264. doi: 10.1016/S0968-0004(00)89039-8. [DOI] [PubMed] [Google Scholar]
  246. Bock SCC. Antithrombin III and Heparin Cofactor II. In: Colman RW, Hirsh J, Marr VJ, editors. Hemostasis and Thrombosis. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 321–333. [Google Scholar]
  247. Kottke-Marchand K, Duncan A. Antithrombin Deficiency. Arch Pathol Lab Med. 2002;126:1326–1336. doi: 10.5858/2002-126-1326-AD. [DOI] [PubMed] [Google Scholar]
  248. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency – a model for conformational diseases. N Engl J Med. 2002;346:45–53. doi: 10.1056/NEJMra010772. [DOI] [PubMed] [Google Scholar]
  249. Lammert F, Gressner A, Ritter K, Matern S. Leber und Gallenblase/-wege. In: Guder WG, Nolte J, editors. Das Laborbuch für Klinik und Praxis. München, Jena: Elsevier Urban & Fischer; 2005. pp. 158–159. [Google Scholar]
  250. Biedermann A, Köhnlein T. Alpha-1-Antitrypsin-Mangel – eine versteckte Ursache der COPD. Dtsch Ärztelbl. 2006;103:A1828. [Google Scholar]
  251. Laposata M, Green D, Van Cott EM et al (1998) College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: the Clinical Use and Laboratory Monitoring of Low-Molecular-Weight Heparin, Danaparoid, Hirudin and Related Compounds, and Argatroban. Arch Pathol Lab Med 122:799-807 [PubMed]
  252. Koeppen KM, Heller S. Differentialblutbild (panoptische Färbung) In: Boll I, Heller S, editors. Praktische Blutzelldiagnostik. Berlin Heidelberg New York: Springer-Verlag; 1991. p. 173. [Google Scholar]
  253. BIPM, IEC, IFCC, ILAC, ISO, IUPAC, IUPAP, OIML . Internationales Wörterbuch der Metrologie (VIM) Deutsch-englische Fassung. Berlin: Beuth-Verlag; 2010. p. 2007. [Google Scholar]
  254. Yung-Chang Chen, Chen-Yin Chen, Hsiang-Hao Hsu, Chung-Wei Yang, Ji Tseng Fang. APACHE III Scoring System in Critically Ill Patients with Acute Renal Failure Requiring Dialysis. Dialysis Transplantation. 2002;31:222–233. [Google Scholar]
  255. Hesse A, Claßen A, Röhle G. Labordiagnostik bei Urolithiasis. Stuttgart: WVG; 1989. [Google Scholar]
  256. Asper A. Harnsteinanalytik. Habilitationsschrift. Zürich: Medizinische Fakultät; 1982. [Google Scholar]
  257. Falbe J, Regitz M. Römpp Chemie Lexikon. Stuttgart New York: Thieme Verlag; 1996. [Google Scholar]
  258. Schwandt P, Richter O, Parhofer KG. Handbuch der Fettstoffwechselstörungen. Stuttgart: Schattauer Verlag; 2007. [Google Scholar]
  259. Schwandt P, Richter O, Parhofer KG. Handbuch der Fettstoffwechselstörungen. Stuttgart: Schattauer Verlag; 2007. [Google Scholar]
  260. Hubacek JA. Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants. Clin Chem Lab Med. 2005;43:897–902. doi: 10.1515/CCLM.2005.153. [DOI] [PubMed] [Google Scholar]
  261. Schwandt P, Richter O, Parhofer KG. Handbuch der Fettstoffwechselstörungen. Stuttgart: Schattauer Verlag; 2007. [Google Scholar]
  262. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507–537. doi: 10.1146/annurev.genom.1.1.507. [DOI] [PubMed] [Google Scholar]
  263. Day JR, Albers JJ, Gilbert TL, et al. Purification and molecular cloning of human apolipoprotein F. Biochem Biophys Res Commun. 1994;203:1146–1151. doi: 10.1006/bbrc.1994.2302. [DOI] [PubMed] [Google Scholar]
  264. Jones SE, Jomary C. Clusterin. 2002;34:427–431. doi: 10.1016/s1357-2725(01)00155-8. [DOI] [PubMed] [Google Scholar]
  265. Ghosh P, Hale EA, Lakshman MR. Plasma sialic-acid index of apolipoprotein J (SIJ): a new alcohol intake marker. Alcohol. 2001;25:173–179. doi: 10.1016/S0741-8329(01)00187-2. [DOI] [PubMed] [Google Scholar]
  266. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med. 2005;11:418–422. doi: 10.1038/nm1211. [DOI] [PubMed] [Google Scholar]
  267. Christoffersen C, Dahlbäck B, Nielsen LB. Apolipoprotein M: progress in understanding its regulation and metabolic functions. Scand J Clin Lab Invest. 2006;66:631–638. doi: 10.1080/00365510600885500. [DOI] [PubMed] [Google Scholar]
  268. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci USA. 1996;93:2239–2244. doi: 10.1073/pnas.93.6.2239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  269. Hilgers R-D, Bauer P, Scheiber V. Einführung in die Medizinische Statistik. Berlin Heidelberg New York: Springer-Verlag; 2002. [Google Scholar]
  270. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) Plots: A fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–577. [PubMed] [Google Scholar]
  271. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249:505–510. doi: 10.1126/science.2200121. [DOI] [PubMed] [Google Scholar]
  272. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346:818–822. doi: 10.1038/346818a0. [DOI] [PubMed] [Google Scholar]
  273. Bunka DH, Stockley PG. Aptamers come of age – at last. Nat Rev Microbiol. 2006;4(8):588–596. doi: 10.1038/nrmicro1458. [DOI] [PubMed] [Google Scholar]
  274. Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5(2):123–132. doi: 10.1038/nrd1955. [DOI] [PubMed] [Google Scholar]
  275. Apt L, Downey WS. Melena neonatorum: The swallowed blood syndrome; a simple test for the differentiation of adult and fetal hemoglobin in bloody stools. J Pediatr. 1955;47:6–12. doi: 10.1016/S0022-3476(55)80118-7. [DOI] [PubMed] [Google Scholar]
  276. Thomas L. Labor und Diagnose. 6. Frankfurt/Main: THBooks; 2005. p. 1918f. [Google Scholar]
  277. Latscha HP, Linti GW, Klein HA. Analytische Chemie. Chemie – Basiswissen III. Berlin Heidelberg New York: Springer-Verlag; 2004. [Google Scholar]
  278. Thomas L. Arbeitsgemeinschaft Medizinische Laboratoriumsdiagnostik (AML) gegründet. Lab Med. 1994;18:342. [Google Scholar]
  279. DFG . MAK- und BAT-Werte-Liste 2008. Weinheim: Wiley-VCH; 2008. [Google Scholar]
  280. Die Verordnung zum Schutz vor gefährlichen Stoffen (Gefahrstoffverordnung – GefStoffV) (2010) Bundesgesetzblatt I, S. 1643
  281. Bundesministerium für Arbeit und Soziales. http://www.bmas.de/DE/Service/Gesetze/arbschg.html
  282. http://www.nobel.se/medicine/laureates/1978/arber-autobio.html
  283. Duran M. Amino acids. In: Blau N, Duran M, Gibson KM, editors. Laboratory Guide to the Methods in Biochemical Genetics. Berlin Heidelberg New York: Springer; 2008. pp. 53–90. [Google Scholar]
  284. Flynn NE, Meininger CJ, Haynes TE, et al. The metabolic basis of arginine nutrition and pharmacology. Biomed Pharmacother. 2002;56:427–438. doi: 10.1016/S0753-3322(02)00273-1. [DOI] [PubMed] [Google Scholar]
  285. Bremer HJ, Duran M, Kamerling JP, et al. Disturbances of Aminoacid Metabolism: Clinical Chemistry and Diagnosis. Munich and Baltimore: Urban & Schwarzenberg; 1981. [Google Scholar]
  286. Duran M. Amino acids. In: Blau N, Duran M, Gibson KM, editors. Laboratory Guide to the Methods in Biochemical Genetics. Berlin Heidelberg New York: Springer; 2008. pp. 53–90. [Google Scholar]
  287. Newton CR, Graham A, Heptinstall IE, et al. Analysis of Any Point Mutation in DNA. The Amplification Refractory Mutation System (ARMS) Nucleic Acids Res. 1989;17:2503–2515. doi: 10.1093/nar/17.7.2503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  288. Geisler J, Ekse D, Helle H, et al. An optimized, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Mol Biol. 2008;109:90–95. doi: 10.1016/j.jsbmb.2007.12.011. [DOI] [PubMed] [Google Scholar]
  289. Satoh K, Nonaka R, Ishikawa F, et al. In vitro screening assay for detecting aromatase activity using rat ovarian microsomes and estrone ELISA. Biol Pharm Bull. 2008;31:357–362. doi: 10.1248/bpb.31.357. [DOI] [PubMed] [Google Scholar]
  290. Degel F. Aromatics (BTEX) In: Külpmann WR, editor. Clincial toxicological analysis. Weinheim: Wiley-VCH; 2009. pp. 523–531. [Google Scholar]
  291. Kommission „Human-Biomonitoring“ des Umweltbundesamtes Stoffmonographie Arsen – Referenzwert für Urin. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2003;46:1098–1106. doi: 10.1007/s00103-003-0710-6. [DOI] [PubMed] [Google Scholar]
  292. BIPM, IEC, IFCC, ILAC, ISO, IUPAC, IUPAP, OIML . Internationales Wörterbuch der Metrologie (VIM) Deutsch-englische Fassung. Berlin: Beuth-Verlag; 2010. p. 2007. [Google Scholar]
  293. Tryding N, Tufvesson C, Sonntag O (1996) Drug Effects in Clinical Chemistry. Clinically Important Analytical Interferences and Biological Effects of Drugs on Biochemical and Haematological Laboratory Investigations. 7th edn. AB Realtryk, Stockholm
  294. Young DS (2000) Effects of Drugs on Clinical Laboratory Tests. 5th edn. AACC Press, Washington DC
  295. Gladtke E, von Hattingberg HM. Pharmakokinetik. Berlin Heidelberg New York: Springer-Verlag; 1973. [Google Scholar]
  296. Ashby W. The determination of the length of life of transfused blood corpuscles in man. J Exp Med. 1919;29:267–281. doi: 10.1084/jem.29.3.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  297. Arndt T. Asialotransferrin – An alternative to carbohydrate- deficient transferrin? Clin Chem. 2003;49:1022–1023. doi: 10.1373/49.6.1022. [DOI] [PubMed] [Google Scholar]
  298. Wallace RB, Johnson MJ, Hirose T, et al. The Use of Synthetic Oligonucleotides as Hybridization Probes. II. Hybridization of Oligonucleotides of Mixed Sequence to Rabbit β-Globin DNA. Nucleic Acids Res. 1981;9:879–894. doi: 10.1093/nar/9.4.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  299. Bremer HJ, Duran M, Kamerling JP, et al. Disturbances of Aminoacid Metabolism: Clinical Chemistry and Diagnosis. Munich and Baltimore: Urban & Schwarzenberg; 1981. [Google Scholar]
  300. Duran M. Amino acids. In: Blau N, Duran M, Gibson KM, editors. Laboratory Guide to the Methods in Biochemical Genetics. Berlin Heidelberg New York: Springer; 2008. p. p53. [Google Scholar]
  301. Bremer HJ, Duran M, Kamerling JP, et al. Disturbances of Aminoacid Metabolism: Clinical Chemistry and Diagnosis. Munich and Baltimore: Urban & Schwarzenberg; 1981. [Google Scholar]
  302. Duran M. Amino acids. In: Blau N, Duran M, Gibson KM, editors. Laboratory Guide to the Methods in Biochemical Genetics. Berlin Heidelberg New York: Springer; 2008. p. p53. [Google Scholar]
  303. Schumann G, et al. IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37 °C, Part 5: Reference Procedure for the Measurement of Catalytic Concentration of Aspartate Aminotransferase. Clin Chem Lab Med. 2002;40:725–733. doi: 10.1515/CCLM.2002.125. [DOI] [PubMed] [Google Scholar]
  304. Ohmori T, Yatomi Y, Nonaka T, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost. 2006;4:1271–1278. doi: 10.1111/j.1538-7836.2006.01958.x. [DOI] [PubMed] [Google Scholar]
  305. Berzofsky JA, Epstein SL, Berkower IJ (1989) Antigenantibody interactions and monoclonal antibodies. In: Paul WA (ed) Fundamental Immunology. 2nd edn. Raven Press, New York
  306. Siggaard-Andersen O, Engel K, Jorgensen K, Astrup P. A Micro Method for the Determination of pH, Carbon Dioxide Tension, Base Excess and Standard Bicarbonate in Capillary Blood. Scand J Clin Lab Invest. 1960;12:172–176. doi: 10.3109/00365516009062419. [DOI] [PubMed] [Google Scholar]
  307. Cannon RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998;44:1809–1819. [PubMed] [Google Scholar]
  308. Schwedhelm E, Böger RH. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol. 2011;5:275–285. doi: 10.1038/nrneph.2011.31. [DOI] [PubMed] [Google Scholar]
  309. Braden B, Lembcke B, Caspary WF. Nichtinvasive Funktionsdiagnostik aus der Atemluft mit 13C-Atemtests. Dt Ärzteblatt. 2003;100:A3376. [Google Scholar]
  310. Henning BF, Doberauer C, Tepel M, Gillessen A. H2-Atemtests. Internist Praxis. 1997;37:745–757. [Google Scholar]
  311. Schneider ARJ, Caspary WF, Stein J. 13C-basierte Atemtests in der Leberfunktionsdiagnostik. Z Gastroenterol. 2004;42:269–275. doi: 10.1055/s-2004-812833. [DOI] [PubMed] [Google Scholar]
  312. Sperl W, Freisinger P. Mitochondriale Enzephalomyopathien im Kindesalter – kritische Aspekte zu Diagnostik und Therapie. Heilbronn: SPS Publications; 2004. [Google Scholar]
  313. Welz B, Sperling M. Atomabsorptionsspektrometrie. 4. Weinheim: Wiley-VCH; 1997. [Google Scholar]
  314. Broekaert JAC. Analytical Spectrometry with Flames and Plasmas. Weinheim: Wiley-VCH; 2002. [Google Scholar]
  315. Broekaert JAC. Analytical Spectrometry with Flames and Plasmas. Weinheim: Wiley-VCH; 2002. [Google Scholar]
  316. Welz B, Sperling M. Atomabsorptionspektrometrie. 4. Weinheim: Wiley-VCH; 1997. [Google Scholar]
  317. Broekaert JAC. Analytical Atomic Spectrometry with Flames and Plasmas. Weinheim: Wiley-VCH; 2002. [Google Scholar]
  318. Kellner R, et al. Analytical Chemistry. 2. Weinheim: Wiley-VCH; 2004. [Google Scholar]
  319. Altmann DG, Bland JM. Statistical Notes: Diagnostic tests 3: receiver operating characteristic plots. BMJ. 1994;309:188. doi: 10.1136/bmj.309.6948.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  320. DIN EN ISO 9000:2005 „Qualitätsmanagementsysteme – Grundlagen und Begriffe“
  321. Auer J. Some hitherto undescribed structures found in the large lymphocytes of a case of acute leukaemia. Am J Med Sci. 1906;131:1002–1015. doi: 10.1097/00000441-190606000-00008. [DOI] [Google Scholar]
  322. BIPM, IEC, IFCC, ILAC, ISO, IUPAC, IUPAP, OIML . Internationales Wörterbuch der Metrologie (VIM) Deutsch-englische Fassung. ISO/IEC-Leitfaden 99:2007. 3. Berlin: Beuth-Verlag; 2010. [Google Scholar]
  323. Ettre LS. Nomenclature for Chromatography. Pure Appl Chem. 1993;65:819–872. doi: 10.1351/pac199365040819. [DOI] [Google Scholar]
  324. Buschhausen-Denker G, Deitenbeck D. Sicherheit in der Gentechnik. Handbuch für Projektleiter und Mitarbeiter in gentechnischen Anlagen. Bremen: Ed. Temmen; 1995. [Google Scholar]
  325. Falbe J, Regitz M, editors. Römpp Chemie Lexikon. Stuttgart New York: Georg Thieme Verlag; 1989. [Google Scholar]
  326. BIPM, IEC, IFCC, ILAC, ISO, IUPAC, IUPAP, OIML . Internationales Wörterbuch der Metrologie (VIM) Deutschenglische Fassung. ISO/IEC-Leitfaden 99:2007. 3. Berlin: Beuth-Verlag; 2010. [Google Scholar]
  327. Weiß C. Basiswissen Medizinische Statistik. Berlin Heidelberg New York: Springer- Verlag; 1999. [Google Scholar]
  328. ISO Statistics (1993) Vocabulary and symbols. Part 1. Probability and general statistical terms. ISO 3534-1, Geneva
  329. Falbe J, Regitz M, editors. Römpp Chemie Lexikon. Stuttgart New York: Georg Thieme Verlag; 1989. [Google Scholar]
  330. Ettre LS. Nomenclature for Chromatography. Pure Appl Chem. 1993;65:819–872. doi: 10.1351/pac199365040819. [DOI] [Google Scholar]
  331. Unger KK, editor. Handbuch der HPLC. Teil 1 Leitfaden für Anfänger und Praktiker. Darmstadt: GIT Verlag; 1989. [Google Scholar]
  332. American Association of Blood Banks . Technical Manual 13th edition. Basel: S. Karger; 1999. [Google Scholar]
  333. Salama A, Mueller-Eckhardt C. Nachweis von erythrozytären Antigenen und Antikörpern. In: Mueller-Eckhardt C, editor. Transfusionsmedizin. Heidelberg Berlin New York: Springer; 1996. pp. 587–596. [Google Scholar]
  334. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol. 1992;99:243–250. doi: 10.1111/1523-1747.ep12616580. [DOI] [PubMed] [Google Scholar]
  335. Jainta S, Schmidt E, Bröcker EB, Zillikens D. Diagnostik und Therapie bullöser Autoimmunerkrankungen der Haut. Deutsches Ärzteblatt. 2001;98:A1320. [Google Scholar]
  336. Sitaru C, Dähnrich C, Probst C, Komorowski L, Blöcker I, Schmidt E, Schlumberger W, Rose C, Stöcker W, Zillikens D. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol. 2007;16:770–777. doi: 10.1111/j.1600-0625.2007.00592.x. [DOI] [PubMed] [Google Scholar]
  337. Dilling A, Rose C, Hashimoto T, Zillikens D, Shimanovich I. Anti-p-200-Pemphigoid: a novel autoimmune subepidermal blistering disease. J Dermatol. 2007;34:1–8. doi: 10.1111/j.1346-8138.2007.00208.x. [DOI] [PubMed] [Google Scholar]
  338. Preisz K, Kárpáti S. Paraneoplastic Pemphigus. Orv Hetil. 2007;148(21):979–983. doi: 10.1556/OH.2007.27955. [DOI] [PubMed] [Google Scholar]
  339. Dainichi T, Kurono S, Ohyama B, Ishii N, Sanzen N, Hayashi M, Shimono C, Taniguchi Y, Koga H, Karashima T, Yasumoto S, Zillikens D, Sekiguchi K, Hashimoto T. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci USA. 2009;106(8):2800–2805. doi: 10.1073/pnas.0809230106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  340. Probst C, Schlumberger W, Stöcker W, Recke A, Schmidt E, Hashimoto T, Zhu XJ, Zillikens D, Komorowski L. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta. 2009;410(1–2):13–18. doi: 10.1016/j.cca.2009.08.022. [DOI] [PubMed] [Google Scholar]
  341. McConville J, Vincent A. Diseases of the neuromuscular junction. Curr Opin Pharmacol. 2002;2:296–301. doi: 10.1016/S1471-4892(02)00156-X. [DOI] [PubMed] [Google Scholar]
  342. Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000;23:453–477. doi: 10.1002/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  343. Wallukat K. The β-adrenergic receptors. Herz. 2002;27:683–690. doi: 10.1007/s00059-002-2434-z. [DOI] [PubMed] [Google Scholar]
  344. Jahns R, Boivin V, Hein L, et al. Direct evidence for a β1- adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113:1419–1429. doi: 10.1172/JCI20149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  345. Caforio AL, Daliento L, Angelini A, et al. Autoimmune myocarditis and dilated cardiomyopatha: focus on cardiac autoantibodies. Lupus. 2005;14:652–655. doi: 10.1191/0961203305lu2193oa. [DOI] [PubMed] [Google Scholar]
  346. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum. 1980;23:881–888. doi: 10.1002/art.1780230802. [DOI] [PubMed] [Google Scholar]
  347. Bernstein RM, Morgan SH, Chapman J, Bunn CC, Mathews MB, Warwick M, Hughes GR. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J. 1984;289:151–152. doi: 10.1136/bmj.289.6438.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  348. Azad AK, Stanford DR, Sarkar S, Hopper AK. Role of nuclear poos of aminoacyl-t-RNA synthetases in tRNA nuclear export. Mol Biol Cell. 2001;12(5):1381–1392. doi: 10.1091/mbc.12.5.1381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  349. Saiz A, Dalmau J, Butler MH, et al. Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry. 1999;66:214–217. doi: 10.1136/jnnp.66.2.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  350. Rand JH, Wu XX, Lapinski R, van Heerde WL, Reutelingsperger CP, Chen PP, Ortel TL. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood. 2004;104:2783–2790. doi: 10.1182/blood-2004-01-0203. [DOI] [PubMed] [Google Scholar]
  351. Tomer A, Bar-Lev S, Fleisher S, Shenkman B, Friger M, Abu-Shakra M. Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool. Brit J Haematol. 2007;139:113–120. doi: 10.1111/j.1365-2141.2007.06751.x. [DOI] [PubMed] [Google Scholar]
  352. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet. 2004;364:2106–2112. doi: 10.1016/S0140-6736(04)17551-X. [DOI] [PubMed] [Google Scholar]
  353. Weinshenker BG, Wingerchuk DM. Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol. 2008;318:343–356. doi: 10.1007/978-3-540-73677-6_14. [DOI] [PubMed] [Google Scholar]
  354. Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stöcker W, Wandinger KP. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci. 2010;291:52–56. doi: 10.1016/j.jns.2010.01.002. [DOI] [PubMed] [Google Scholar]
  355. McFarlane BM, McSorley CG, Vergani D, et al. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol. 1986;3:196–205. doi: 10.1016/S0168-8278(86)80026-5. [DOI] [PubMed] [Google Scholar]
  356. Schultz H, Weiss J, Carroll SF, Gross WL. The endotoxin- binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies. J leukoc Biol. 2001;69:505–512. [PubMed] [Google Scholar]
  357. Vincent A. Antibodies to ion channels in paraneoplastic disorders. Brain Pathology. 1999;9:285–291. doi: 10.1111/j.1750-3639.1999.tb00227.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  358. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–1474. doi: 10.1056/NEJM199506013322203. [DOI] [PubMed] [Google Scholar]
  359. Autoantikörper gegen Phospholipide
  360. Casiano CA, Humbel RL, Peebles C, et al. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENPF in disorders associated with cell proliferation. J Autoimmunity. 1995;8:575–586. doi: 10.1016/0896-8411(95)90009-8. [DOI] [PubMed] [Google Scholar]
  361. Casiano CA, Landberg G, Ochs RL, et al. Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis. J Cell Sci. 1993;106:1045–1056. doi: 10.1242/jcs.106.4.1045. [DOI] [PubMed] [Google Scholar]
  362. Vossenaar ER, Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev. 2004;4:239–262. doi: 10.1016/j.cair.2003.11.001. [DOI] [Google Scholar]
  363. Jelezarova E, Schlumberger M, Sadallah S, et al. A C3 convertase assay for nephritic factor functional activity. J Immunol Methods. 2001;251:45–52. doi: 10.1016/S0022-1759(01)00295-2. [DOI] [PubMed] [Google Scholar]
  364. Siegert CEH, Kazatchkine MD, Sjöholm A, Würzner R, Loos M, Daha MR. Autoantibodies against C1q: view on clinical relevance and pathogenic roles. Clin Exp Immunol. 1999;116:4–8. doi: 10.1046/j.1365-2249.1999.00867.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  365. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res. 2002;4(3):S279. doi: 10.1186/ar586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  366. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest. 1999;103:461–468. doi: 10.1172/JCI5252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  367. Dähnrich C, Rosemann A, Probst C, Komorowski L, Schlumberger W, Stöcker W, Recke A, Rose C, Zillikens D, Schmidt E (2009) ELISA using ectodomains of desmoglein 1 and 3 expressed in HEK293 for sensitive and specific detection of pemphigus autoantibodies. In: Conrad et al (eds): From pathogenesis to therapy of autoimmune diseases. Pabst Science Publishers Vol. 6:498–499
  368. Isenberg D, Smeenk R. Clinical laboratory assays for measuring anti-dsDNA antibodies. Where are we now? Lupus. 2002;11:797–800. doi: 10.1191/0961203302lu300rr. [DOI] [PubMed] [Google Scholar]
  369. Biesen R, Dähnrich C, Rosemann A, Hiepe F, Egerer K, Stöcker W, Schlumberger W. Anti-dsDNA-NcX ELISA is superior to Farr-RIA and IFA using Crithidia luciliae for SLE diagnosis. Lupus. 2008;17:506–507. [Google Scholar]
  370. Colburn KK, Langga-Shariffi E, Kelly GT, Malto MC, Sandberg LB, Baydanoff S, Green LM. J Investig Med Mar. 2003;51:104–109. doi: 10.2310/6650.2003.34214. [DOI] [PubMed] [Google Scholar]
  371. Zhi Liu. Immunopathology of bullous pemphigoid, an autoimmune and inflammatory skin blistering disease. Keio J Med. 2003;52:128–133. doi: 10.2302/kjm.52.128. [DOI] [PubMed] [Google Scholar]
  372. Sitaru C, Dähnrich C, Probst C, Komorowski L, Blöcker I, Schmidt E, Schlumberger W, Rose C, Stöcker W, Zillikens D. Enzymelinked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol. 2007;16:770–777. doi: 10.1111/j.1600-0625.2007.00592.x. [DOI] [PubMed] [Google Scholar]
  373. Mueller-Eckhard C. Transfusionsmedizin. Berlin Heidelberg New York: Springer- Verlag; 1996. [Google Scholar]
  374. Tan EM, Chan EKL, Sullivan KF, et al. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol. 1988;47:121–141. doi: 10.1016/0090-1229(88)90066-9. [DOI] [PubMed] [Google Scholar]
  375. Czaja AJ. Autoimmune liver diseases. Curr Opin Gastroenterol. 2007;23:255–262. doi: 10.1097/MOG.0b013e328034f234. [DOI] [PubMed] [Google Scholar]
  376. Villalta D, Bizzaro N, Re M, Tozzoli R, Komorowski L, Tonutti E. Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders. Autoimmunity. 2008;41:105–110. doi: 10.1080/08916930701619896. [DOI] [PubMed] [Google Scholar]
  377. Haneji N, Nakamura T, Takio K, et al. Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren’s syndrome. Science. 1997;276:604–607. doi: 10.1126/science.276.5312.604. [DOI] [PubMed] [Google Scholar]
  378. Ulbricht KU, Schmidt RE, Witte T. Antibodies against alphafodrin in Sjogren’s syndrome. Autoimmun Rev. 2003;2:109–113. doi: 10.1016/S1568-9972(03)00002-8. [DOI] [PubMed] [Google Scholar]
  379. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J. Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9:67–76. doi: 10.1016/S1474-4422(09)70324-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  380. Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABAB receptor antibodies in limbic encephalitis and GAD-associated neurologic disorders. Neurology. 2011;76:795–800. doi: 10.1212/WNL.0b013e31820e7b8d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  381. Wandinger KP, Klingbeil C, Gneiss C, Waters P, Dalmau J, Saschenbrecker S, Borowski K, Deisenhammer F, Vincent A, Probst C, Stöcker W. Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis. J Lab Med. 2011;35:329–342. [Google Scholar]
  382. Jeffrey GP, Swanson NR, Yarred LJ, et al. Bile duct antibodies crossreacting with blood group antigens in primary sclerosing cholangitis. Gut. 1990;31:698–701. doi: 10.1136/gut.31.6.698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  383. Vernino S. Autoimmune and paraneoplastic channelopathies. Neurotherapeutics. 2007;4:305–314. doi: 10.1016/j.nurt.2007.01.007. [DOI] [PubMed] [Google Scholar]
  384. Vernino S, Lindstrom, Hopkins J, Wang S, Low Z. Characterization of ganglionic acetylcholine receptor autoantibodies. J Neuroimmunol. 2008;197:63–69. doi: 10.1016/j.jneuroim.2008.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  385. Vernino S. Neuronal acetylcholine receptor autoimmunity. Ann N Y Acad Sci. 2008;1132:124–128. doi: 10.1196/annals.1405.011. [DOI] [PubMed] [Google Scholar]
  386. Heidenreich F (1998) Autoantibodies associated with peripheral neuropathies. In: Conrad K, Humbel RL, Meurer M, Shoenfeld Y, Tan EM (eds) Pathogenic and diagnostic relevance of autoantibodies. Pabst Science Publishers 316–327
  387. Meyer W, Schneider B, Klotz M, Schlumberger W, Stöcker W (2000) EUROLINE ganglioside profile: A new membrane test for the detection of autoantibodies against gangliosides. In: Conrad K et al (eds) Autoantigens and Autoantibodies: Diagnostic Tools and Clues to Understanding Autoimmunity. Pabst Science Publishers 619–620
  388. Seah PP, Fry L, Rossiter MA, et al. Antireticulin antibodies in childhood coeliac disease. Lancet. 1971;2:681–682. doi: 10.1016/S0140-6736(71)92248-3. [DOI] [PubMed] [Google Scholar]
  389. Chorzelski TP, Sulej J, Tchorzewska H, et al. IgA class endomysium antibodies in dermatitis herpetiformis and coeliac disease. Ann NY Acad Sci. 1983;420:325–334. doi: 10.1111/j.1749-6632.1983.tb22220.x. [DOI] [PubMed] [Google Scholar]
  390. Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of coeliac disease. Nat Med. 1997;3:797–801. doi: 10.1038/nm0797-797. [DOI] [PubMed] [Google Scholar]
  391. Freitag T, Schulze-Koops H, Niedobitek G, et al. The role of the immune response against tissue transglutaminase in the pathogenesis of coeliac disease. Autoimmun Rev. 2004;3:13–20. doi: 10.1016/S1568-9972(03)00054-5. [DOI] [PubMed] [Google Scholar]
  392. Johnson GD, Holborow EJ, Glynn LE. Antibody to smooth muscle in patients with liver disease. Lancet. 1965;2:878–879. doi: 10.1016/S0140-6736(65)92505-5. [DOI] [PubMed] [Google Scholar]
  393. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler CH, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135. doi: 10.1136/jnnp.2003.034447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  394. Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70:924–928. doi: 10.1212/01.wnl.0000281663.81079.24. [DOI] [PubMed] [Google Scholar]
  395. Hellmark T, Johannson C, Wieslander J. Characterization of anti-GBM antibodies involved in Goodpasture’s syndrome. Kidney Int. 1994;46:823–829. doi: 10.1038/ki.1994.338. [DOI] [PubMed] [Google Scholar]
  396. Bolton WK, Chen L, Hellmark T, Fox J, Wieslander J. Molecular mapping of the Goodpasture’s epitope for glomerulonephritis. Trans Am Clin Climatol Assoc. 2005;116:237–238. [PMC free article] [PubMed] [Google Scholar]
  397. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, Camilli P. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990;347:151–156. doi: 10.1038/347151a0. [DOI] [PubMed] [Google Scholar]
  398. Stöcker W, Schaper J, Schuhose C, Vieregge P, Kömpf D, Scriba PC. Autoantibodies against cerebral gray matter in patients with insulin dependent diabetes mellitus. Immunobiol. 1990;181:223. [Google Scholar]
  399. Vieregge P, Branczyk B, Barnett W, Stöcker W, Soyka D, Kömpf D. Stiff-Man-Syndrom. Bericht über vier Fälle. 1994;65:712–717. [PubMed] [Google Scholar]
  400. Pozzilli P, Manfrini S, Monetini L. Biochemical markers of type 1 diabetes: clinical use. Scand J Clin Lab Invest. 2001;61(235):38–44. doi: 10.1080/003655101753352031. [DOI] [PubMed] [Google Scholar]
  401. Krüger C, Stöcker W, Schlosser M (2006) Glutamic Acid Decarboxylase Autoantibodies. In: Shoenfeld Y, Gershwin ME, Meroni PL (Hrsg) Autoantibodies. 2. Aufl. Elsevier, pp 369–378
  402. Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen’s encephalitis. Science. 1994;265:648–651. doi: 10.1126/science.8036512. [DOI] [PubMed] [Google Scholar]
  403. Granata T. Rasmussen’s syndrome. Neurol Sci Suppl. 2003;4:239. doi: 10.1007/s10072-003-0086-2. [DOI] [PubMed] [Google Scholar]
  404. Lai M, Hughes EG, Peng X, Zhou L, Gleichmann AJ, Shu H, Matà S, Kremens D, Vitaliani R, Geschwind MD, Bataller L, Kalb RG, Davis R, Graus F, Lynch DR, Balice-Gordon R, Dalmau J. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65:424–434. doi: 10.1002/ana.21589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  405. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurology. 2008;7:1091–1098. doi: 10.1016/S1474-4422(08)70224-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  406. Prüss H, Dalmau J, Harms L, Höltje M, Ahnert-Hilger G, Borowski K, Stoecker W, Wandinger KP. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology. 2010;75:1735–1739. doi: 10.1212/WNL.0b013e3181fc2a06. [DOI] [PubMed] [Google Scholar]
  407. Wandinger KP, Klingbeil C, Gneiss C, Waters P, Dalmau J, Saschenbrecker S, Borowski K, Deisenhammer F, Vincent A, Probst C, Stöcker W. Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis. J Lab Med. 2011;35:329–342. [Google Scholar]
  408. Hutchinson M, Waters P, McHugh J, Gorman G, O’Riordan S, Connolly S, Hager H, Yu P, Becker C-M, Vincent A. Progressive encephalomyelitis, rigidity, and myoclonus: A novel glycine receptor antibody. Neurology. 2008;71:1291–1292. doi: 10.1212/01.wnl.0000327606.50322.f0. [DOI] [PubMed] [Google Scholar]
  409. Turner M, Irani S, Leite M, Nithi K, Vincent A, Ansorge O. Progressive encephalomyelitis with rigidity and myoclonus: Glycine and NMDA receptor antibodies. Neurology. 2011;77:439. doi: 10.1212/WNL.0b013e318227b176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  410. Piotrowicz A, Thümen A, Leite MI, Vincent A, Moser A. A case of glycine-receptor-associated encephalomyelitis with rigidity and myoclonus (PERM): clinical course, treatment and CSF findings. J Neurol. 2011;258:2268–2270. doi: 10.1007/s00415-011-6078-x. [DOI] [PubMed] [Google Scholar]
  411. Mas N, Saiz A, Leite MI, Waters P, Baron M, Castano D, Sabater L, Vincent A, Graus F. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry. 2011;82:1399–1401. doi: 10.1136/jnnp.2010.229104. [DOI] [PubMed] [Google Scholar]
  412. Wandinger KP, Klingbeil C, Gneiss C, Waters P, Dalmau J, Saschenbrecker S, Borowski K, Deisenhammer F, Vincent A, Probst C, Stöcker W. Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis. J Lab Med. 2011;35:329–342. [Google Scholar]
  413. Courvalin J-C, Lassoued K, Bartnik E, Blobel G, Wozniak RW. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. Clin Invest. 1990;86:279–285. doi: 10.1172/JCI114696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  414. Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. Antigp210 antibodies in sera of patients with primary biliary cirrhosis. Identification of a 64-kD fragment of gp210 as a major epitope. Hum Antibodies Hybridomas. 1996;7:167–174. [PubMed] [Google Scholar]
  415. Szostecki C, Guldner HH, Will H. Autoantibodies against „nuclear dots“ in primary biliary cirrhosis. Semin Liver Dis. 1997;17:71–78. doi: 10.1055/s-2007-1007184. [DOI] [PubMed] [Google Scholar]
  416. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis. 2005;25:298–310. doi: 10.1055/s-2005-916321. [DOI] [PubMed] [Google Scholar]
  417. Levine JS, Branch DW, Rauch J. The Antiphospholipid Syndrome. N Engl J Med. 2002;346:752–763. doi: 10.1056/NEJMra002974. [DOI] [PubMed] [Google Scholar]
  418. McNeil HP, Simpson RJ, Chesterman CN, et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) Proc Natl Acad Sci USA. 1990;87:4120–4124. doi: 10.1073/pnas.87.11.4120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  419. Wilson WA, Gharavi AE, Koike T. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 1999;42:1309–1311. doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  420. Stinton LM, Eystathioy T, Selak S, et al. Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clin Immunol. 2004;110:30–44. doi: 10.1016/j.clim.2003.10.005. [DOI] [PubMed] [Google Scholar]
  421. Van Der Woude FJ, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and a marker of disease activity in Wegener’s granulomatosis. Lancet. 1985;1:425–429. doi: 10.1016/S0140-6736(85)91147-X. [DOI] [PubMed] [Google Scholar]
  422. Gross WL. Antineutrophil cytoplasmic autoantibody testing in vasculitides. Rheum Dis Clin North Am. 1995;21:987–1011. [PubMed] [Google Scholar]
  423. Damoiseaux J, Buschtez M, Steller U, Zerbe B, Rosemann A, Fechner K, Schlumberger W, Cohen Tervaert JW, Stöcker W (2007) EUROPLUSTM ANCA BIOCHIP Mosaic: MPO and PR3 antigen dots improve the detection of ANCA by indirect immunofluorescence. In: Conrad K et al (eds) From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies. Pabst Science Publishers, 5:485–486
  424. Damoiseaux J, Dähnrich C, Rosemann A, Probst C, Komorowski L, Stegeman CA, Egerer K, Hiepe F, Paassen PV, Stöcker W, Schlumberger W, Tervaert JWC. A novel ELISA using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for ANCA-associated vasculitis. Ann Rheum Dis. 2009;68:228–233. doi: 10.1136/ard.2007.086579. [DOI] [PubMed] [Google Scholar]
  425. Komorowski L, Teegen B, Probst C, Schlumberger W, Stöcker W (2009) ELISA for the detection of autoantibodies against DNA-bound lactoferrin in ulcerative colitis. In: Conrad K et al (eds) From Pathogenesis to the Therapy of Autoimmune Diseases. Pabst Science Publishers, pp 474–475
  426. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ. Direct evidence for a beta 1-adrenergic receptor- directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113:1419–1429. doi: 10.1172/JCI20149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  427. Störk S, Boivin V, Horf R, Hein L, Lohse MJ, Angermann CE, Jahns R. Stimulating autoantibodies directed against the cardiac beta-1- adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J. 2006;152:697–704. doi: 10.1016/j.ahj.2006.05.004. [DOI] [PubMed] [Google Scholar]
  428. Bernstein RM, Hobbs RN, Lea DJ, et al. Patterns of antihistone antibody specificity in systemic rheumatic disease. I Systemic lupus erythematosus, mixed connective tissue disease, primary sicca syndrome, and rheumatoid arthritis with vasculitis. Arthr Rheum. 1985;28:285–293. doi: 10.1002/art.1780280308. [DOI] [PubMed] [Google Scholar]
  429. Xu Q, Kiechl S, Mayr M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation. 1999;100:1169–1174. doi: 10.1161/01.CIR.100.11.1169. [DOI] [PubMed] [Google Scholar]
  430. Voltz R. Paraneoplastische neurologische Autoimmunerkrankungen. Nervenarzt. 2002;73:909–929. doi: 10.1007/s00115-002-1407-z. [DOI] [PubMed] [Google Scholar]
  431. Cunningham-Rundles C. IgA Autoantibodies. In: Peter JB, Shoenfeld Y, editors. Autoantibodies. Amsterdam: Elsevier; 1996. pp. 417–422. [Google Scholar]
  432. Strober W, Wochner RD, Barlow MH, et al. Immunoglobulin metabolism in ataxia telangiectasia. J Clin Invest. 1968;47:1905–1915. doi: 10.1172/JCI105881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  433. Hide M, Francis DM, Grattan CE, et al. The pathogenesis of chronic urticaria: new evidence suggest an auto-immune basis and implications for treatment. Clin Exp Allergy. 1994;24:624–627. doi: 10.1111/j.1365-2222.1994.tb00965.x. [DOI] [PubMed] [Google Scholar]
  434. Taylor SI, Barbetti F, Accili D, Roth J, Gorden P. Syndromes of autoimmunity and hypoglycemia. Autoantibodies directed against insulin and its receptor. Endocrinol Metab Clin North Am Mar. 1989;18(1):123–143. [PubMed] [Google Scholar]
  435. Pozzilli P, Manfrini S, Monetini L. Biochemical markers of type 1 diabetes: clinical use. Scand J Clin Lab Invest. 2001;235:38–44. doi: 10.1080/003655101753352031. [DOI] [PubMed] [Google Scholar]
  436. Kiechle FL, Moore KH. Insulin action and the clinical laboratory. J Clin Ligand Assay. 2001;24:217–228. [Google Scholar]
  437. Page KA, Dejardin S, Kahn CR, Kulkarni RN, Herold KC, Inzucchi SE. A patient with type B insulin resistance syndrome, responsive to immune therapy. Nat Clin Pract Endocrinol Metab. 2007;3:835–840. doi: 10.1038/ncpendmet0693. [DOI] [PubMed] [Google Scholar]
  438. Lan MS, Wasserfall C, MacLaren NK, Notkin AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci. 1996;93:6367–6370. doi: 10.1073/pnas.93.13.6367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  439. Pozzilli P, Manfrini S, Monetini L. Biochemical markers of type 1 diabetes: clinical use. Scand J Clin Lab Invest. 2001;235:38–44. doi: 10.1080/003655101753352031. [DOI] [PubMed] [Google Scholar]
  440. Broberger O, Perlman P. Autoantibodies in human ulcerative colitis. J Exp Med. 1959;110:657–674. doi: 10.1084/jem.110.5.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  441. Stöcker W, Otte M, Ulrich S, Normann D, Stöcker K, Jantschek G. Autoantikörper gegen exokrines Pankreas und gegen intestinale Becherzellen in der Diagnostik des Morbus Crohn und der Colitis ulcerosa. Dtsch Med Wschr. 1984;109:1963–1969. doi: 10.1055/s-2008-1069485. [DOI] [PubMed] [Google Scholar]
  442. Stöcker W, Otte M, Scriba PC. Zur Immunpathogenese des Morbus Crohn. Dtsch Med Wschr. 1984;109:1984–1986. doi: 10.1055/s-2008-1069489. [DOI] [PubMed] [Google Scholar]
  443. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, Parrat D. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ. 1988;297:1105–1106. doi: 10.1136/bmj.297.6656.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  444. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmatic antibodies associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202–210. doi: 10.1016/S0091-6749(05)80067-3. [DOI] [PubMed] [Google Scholar]
  445. Conrad K, Bachmann M, Stöcker W. Anti-intestinal goblet cell antibodies. In: Shoenfeld Y, Gershwin ME, Meroni PL, editors. Autoantibodies. 2nd. Amsterdam: Elsevier; 2006. pp. 417–422. [Google Scholar]
  446. Mardh S, Ma JY, Song YH, et al. Occurrence of autoantibodies against intrinsic factor, H-K-ATPase, and pepsinogen in atrophic gastritis and rheumatoid arthritis. Scand J Gastroenterol. 1991;26:1089–1096. doi: 10.3109/00365529109003961. [DOI] [PubMed] [Google Scholar]
  447. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice- Gordon R, Cowell JK, Dalmau J. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9:776–785. doi: 10.1016/S1474-4422(10)70137-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  448. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010;133:2734–2748. doi: 10.1093/brain/awq213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  449. Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A, Martinez-Hernandez E, Wilson C, Jacobs D, Lai M, Walker RW, Graus F, Bataller L, Illa I, Markx S, Strauss KA, Peles E, Scherer SS, Dalmau J. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011;69:303–311. doi: 10.1002/ana.22297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  450. Wandinger KP, Klingbeil C, Gneiss C, Waters P, Dalmau J, Saschenbrecker S, Borowski K, Deisenhammer F, Vincent A, Probst C, Stöcker W. Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis. J Lab Med. 2011;35:329–342. [Google Scholar]
  451. Mimori T, Akizuki M, Yamagata H, et al. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest. 1981;68:611–620. doi: 10.1172/JCI110295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  452. Mierau R, Genth E. Diagnostische Bedeutung Sklerodermieund Myositis-assoziierter Autoantikörper. Z Rheumatol. 1995;54:39–49. [PubMed] [Google Scholar]
  453. Bertuch AA, Lundblad V. The Ku heterodimer performs separable activities at double-strand breaks and chromosome termini. Mol Cell Biol. 2003;23:8202–8215. doi: 10.1128/MCB.23.22.8202-8215.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  454. Komorowski L, Teegen B, Probst C, Schlumberger W, Stöcker W (2009) ELISA for the detection of autoantibodies against DNA-bound lactoferrin in ulcerative colitis. In: Conrad K et al (eds) From Pathogenesis to Therapy of Autoimmune Diseases. Pabst Science Publishers: 474–475
  455. Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis. 1997;17:79–90. doi: 10.1055/s-2007-1007185. [DOI] [PubMed] [Google Scholar]
  456. Nesher G, Margalit R, Ashkenazi YJ. Anti-nuclear envelope antibodies: Clinical associations. Semin Arthritis Rheum. 2001;30:313–320. doi: 10.1053/sarh.2001.20266. [DOI] [PubMed] [Google Scholar]
  457. Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nature Medicine. 2008;14(10):1088–1096. doi: 10.1038/nm.1874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  458. Lapierre P, Hajoui O, Homberg JC, et al. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116:643–649. doi: 10.1016/S0016-5085(99)70186-1. [DOI] [PubMed] [Google Scholar]
  459. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Levy VG, Grippon P. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of „autoimmune“ hepatitis. Hepatology. 1987;7:1333–1339. doi: 10.1002/hep.1840070626. [DOI] [PubMed] [Google Scholar]
  460. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest. 1989;83:1066–1072. doi: 10.1172/JCI113949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  461. Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol. 2001;50:339–348. doi: 10.1002/ana.1288. [DOI] [PubMed] [Google Scholar]
  462. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler CH, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–1140. doi: 10.1136/jnnp.2003.034447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  463. Komatsu M, Goto M, Yamamoto A, Toyoshima I, Masamune O. A new autoantibody, anti-210 kDa microtubule associated protein antibody, detected in the serum of patients with various liver diseases and SLE. Nihon Shokakibyo Gakkai Zasshi. 1990;87:2451–2456. [PubMed] [Google Scholar]
  464. Williams RC, Sugiura K, Tan EM. Antibodies to microtubule- associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2004;50:1239–1247. doi: 10.1002/art.20156. [DOI] [PubMed] [Google Scholar]
  465. Meurer M, Hausmann-Martinez-Pardo G, Braun-Falco O. Spectrum of antinuclear and anti-cytoplasmic antibodies in dermatomyositis and polymyositis overlap syndromes. Hautarzt. 1989;40:623–629. [PubMed] [Google Scholar]
  466. Mierau R, Genth E. Diagnostische Bedeutung Sklerodermieund Myositis-assozierter Autoantikörper. Z Rheumatol. 1995;54:39–49. [PubMed] [Google Scholar]
  467. Rozman B, Bozic B, Kos-Golja M, et al. Immunoserological aspects of idiopathic inflammatory muscle disease. Wien Klin Wochenschr. 2000;112:722–727. [PubMed] [Google Scholar]
  468. Berg PA, Klein R. Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: Definition and clinical relevance. Dig Dis. 1992;10:85–101. doi: 10.1159/000171347. [DOI] [PubMed] [Google Scholar]
  469. Jiang XH, Zhong RQ, Yu SQ, Hu Y, Li WW, Kong XT. Construction and expression of a humanized M2 autoantigen trimer and its application in the diagnosis of primary biliary cirrhosis. World J Gastroenterol Jun. 2003;9:1352–1355. doi: 10.3748/wjg.v9.i6.1352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  470. Dähnrich C, Pares A, Caballeria L, Rosemann A, Schlumberger W, Probst C, Mytilinaiou M, Bogdanos D, Vergani D, Stöcker W, Komorowski L. New ELISA for detecting primary biliary cirrhosisspecific antimitochondrial antibodies. Clin Chem. 2009;55:978–985. doi: 10.1373/clinchem.2008.118299. [DOI] [PubMed] [Google Scholar]
  471. Pluk H, van Engelen BG, Pruijn GJM (2011) Anti-Mup44: the first inclusion body myositis-specific autoantibody. In: Conrad K et al (eds) From prediction to prevention of autoimmune diseases: Autoantigens, Autoantibodies, Autoimmunity. Pabst Science Publishers, p 867
  472. Vincent A, Bowen J, Newsom-Davis J, et al. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol. 2003;2:99–106. doi: 10.1016/S1474-4422(03)00306-5. [DOI] [PubMed] [Google Scholar]
  473. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365–368. doi: 10.1038/85520. [DOI] [PubMed] [Google Scholar]
  474. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nature Med. 1999;5:170–175. doi: 10.1038/5532. [DOI] [PubMed] [Google Scholar]
  475. Jaskowski TD, Martins TB, Litwin CM, et al. Immunoglobulin (Ig)M antibody against myelin associated glycoprotein (MAG): A comparison of methods. J Clin Lab Anal. 2004;18:247–250. doi: 10.1002/jcla.20031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  476. Lalive PH, Menge T, Delarasse C, Della Gaspera B, Pham- Dinh D, Villoslada P, von Bündingen HC, Genain CP. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. PNAS. 2006;103:2280–2285. doi: 10.1073/pnas.0510672103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  477. Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, Busch V, Zhou D, Cepok S, Hemmer B. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009;66:833–842. doi: 10.1002/ana.21916. [DOI] [PubMed] [Google Scholar]
  478. McLaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009;183:4067–4076. doi: 10.4049/jimmunol.0801888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  479. Pauli F, Mader S, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R, Deisenhammer F, Reindl M, Berger T. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol. 2011;138:247–254. doi: 10.1016/j.clim.2010.11.013. [DOI] [PubMed] [Google Scholar]
  480. Pröbstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, Villalobos A, Breithaupt C, Weissert R, Jacob U, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011;77:580–588. doi: 10.1212/WNL.0b013e318228c0b1. [DOI] [PubMed] [Google Scholar]
  481. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Vincent A, Palace J (2011) Myelin-oligodendrocyte glycoprotein antibodymediated acute inflammatory demyelinating disease mimicking neuromyelitis optica. Abstract: 5th Joint triennial congress of the European and Americas Committees for treatment and research in multiple sclerosis, Amsterdam, The Netherlands.
  482. Gross WL. Antineutrophil cytoplasmic autoantibody testing in vasculitides. Rheum Dis Clin North Am. 1995;21:987–1011. [PubMed] [Google Scholar]
  483. Anderson JR, Goudie RB, Gray KG, Timbury GC. Autoantibodies in Addison’s disease. Lancet. 1957;272:1123–1124. doi: 10.1016/S0140-6736(57)91687-2. [DOI] [PubMed] [Google Scholar]
  484. Betterle C, Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002;23:327–364. doi: 10.1210/er.23.3.327. [DOI] [PubMed] [Google Scholar]
  485. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004;350:2068–2079. doi: 10.1056/NEJMra030158. [DOI] [PubMed] [Google Scholar]
  486. Chan KH, Vernino S, Lennon VA. ANNA-3 antineuronal antibody: marker of lung cancer-related autoimmunity. Ann Neurol. 2001;50:301–311. doi: 10.1002/ana.1127. [DOI] [PubMed] [Google Scholar]
  487. Steblay RW, Rudofsky U. Renal tubular disease and autoantibodies against tubular basement membrane induced in guinea pigs. J Immunol. 1971;107:589–594. [PubMed] [Google Scholar]
  488. Schlumberger W, Olbrich S, Müller-Kunert E, et al. Autoantikörper-Diagnostik mit der Substratkombination Humane Epithelzellen (HEp-2) und Primatenleber. Differenzierung der Antikörper durch Enzymimmuntests. Lübeck: Eigenverlag der EUROIMMUN AG; 1994. pp. 1–28. [Google Scholar]
  489. Suer W, Dähnrich C, Schlumberger W, Stöcker W. Autoantibodies in SLE but not in scleroderma react with proteinstripped nucleosomes. J Autoimmun. 2004;22:325–334. doi: 10.1016/j.jaut.2004.02.002. [DOI] [PubMed] [Google Scholar]
  490. Stinton LM, Barr SG, Tibbles LA, Yilmaz S, Sar A, Benedikttson H, Fritzler MJ. Autoantibodies in lupus nephritis patients requiring renal transplantation. Lupus. 2007;16:394–400. doi: 10.1177/0961203307078391. [DOI] [PubMed] [Google Scholar]
  491. Wandinger KP, Klingbeil C, Gneiss C, Waters P, Dalmau J, Saschenbrecker S, Borowski K, Deisenhammer F, Vincent A, Probst C, Stöcker W. Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis. J Lab Med. 2011;35:329–342. [Google Scholar]
  492. Blaes F, Grisold W, Grabbe S, Hübner J, Kleeberg U, Krege S, Leypoldt F, Rauer S, Roelcke U, Schreckenberger M, Singer S, Stummer W, Voltz, R, Wandinger KP, Weller M, Wörmann B (2012) Paraneoplastische Syndrome. Leitlinien für Diagnostik und Therapie der Deutschen Gesellschaft für Neurologie. 5., überarb. Aufl. Thieme Verlag (im Druck)
  493. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883–887. doi: 10.1016/0140-6736(92)90926-T. [DOI] [PubMed] [Google Scholar]
  494. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777–1788. [PubMed] [Google Scholar]
  495. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982;30:403–408. doi: 10.1002/ijc.2910300404. [DOI] [PubMed] [Google Scholar]
  496. Bottazzo GF, Florin-Christensen A, Doniach D. Isletcell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974;2:1279–1283. doi: 10.1016/S0140-6736(74)90140-8. [DOI] [PubMed] [Google Scholar]
  497. Stöcker W, Otte M, Ulrich S, Normann D, Stöcker K, Jantschek G. Autoantikörper gegen exokrines Pankreas und gegen intestinale Becherzellen in der Diagnostik des Morbus Crohn und der Colitis ulcerosa. Dtsch Med Wochenschr. 1984;109:1963–1969. doi: 10.1055/s-2008-1069485. [DOI] [PubMed] [Google Scholar]
  498. Stöcker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stöcker K, Jantschek G, Scriba PC. Autoimmunity to pancreatic juice in Crohn’s disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol Suppl. 1987;139:41–52. doi: 10.3109/00365528709089774. [DOI] [PubMed] [Google Scholar]
  499. Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Büning C, Feist E, Conrad K (2009) The zymogen granule membrane glycoprotein GP2 is a major autoantigen of pancreatic antibodies –relevance in diagnostics and pathogenesis of Crohn’s disease. In: Conrad K et al (eds) From pathogenesis to therapy of autoimmune diseases. Pabst Science Publishers, pp 449–462
  500. Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Feist E, Büttner T, Reinhold D, Jungblut PR, Porstmann T, Laass MW, Büning C, Henker J, Conrad K. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn’s disease. Gut. 2009;58:1620–1628. doi: 10.1136/gut.2008.162495. [DOI] [PubMed] [Google Scholar]
  501. Stöcker W, Teegen B, Probst C, Aulinger-Stöcker K, Ludwig D, Glocker MO, and Komorowski L (2009) CUZD1 and GP2 are the exocrine pancreas autoantigens in Crohn’s disease. In: Conrad K et al (eds) From pathogenesis to therapy of autoimmune diseases. Pabst Science Publishers:463–473
  502. Taylor KB, Roitt IM, Doniach D, et al. Autoimmune phenomena in pernicious anaemia: Gastric antibodies. Br Med J. 1962;2:1347–13527. doi: 10.1136/bmj.2.5316.1347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  503. Vernino S, Lennon V. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol. 2000;47:297–305. doi: 10.1002/1531-8249(200003)47:3<297::AID-ANA4>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  504. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler CH, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–1140. doi: 10.1136/jnnp.2003.034447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  505. Miyachi K, Fritzler MJ, Tan CK. Autoantibody to a nuclear antigen in proliferating cells. J Immunol. 1978;121:2228–2234. [PubMed] [Google Scholar]
  506. Kawamura K, Kobayashi Y, Tanaka T, et al. Intranuclear localization of proliferating cell nuclear antigen during the cell cycle in renal cell carcinoma. Anal Quant Cytol Histol. 2000;22:107–113. [PubMed] [Google Scholar]
  507. Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ. M-type Phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21. doi: 10.1056/NEJMoa0810457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  508. Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, Helmchen U, Stahl RA. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26:2526–2532. doi: 10.1093/ndt/gfr247. [DOI] [PubMed] [Google Scholar]
  509. Gunnarsson I, Schlumberger W, Rönnelid J (2011) PLA2 receptor antibodies as serological markers of idiopathic membranous nephritis are absent in active membranous lupus nephritis. In: Conrad K et al (Hrsg) From prediction to prevention of autoimmune diseases: Autoantigens, Autoantibodies, Autoimmunity. Pabst Science Publishers, pp 232–233
  510. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–1311. doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  511. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–1027. doi: 10.1002/art.10187. [DOI] [PubMed] [Google Scholar]
  512. Alarcon-Segovia D, Cabral AR. The anti-phospholipid antibody syndrome: clinical and serological aspects. Baillieres Best Pract Res Clin Rheumatol. 2000;14:139–150. doi: 10.1053/berh.1999.0082. [DOI] [PubMed] [Google Scholar]
  513. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752–763. doi: 10.1056/NEJMra002974. [DOI] [PubMed] [Google Scholar]
  514. Sternsdorf T, Guldner HH, Szostecki C, Grotzinger T, Will H. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand.J Immunol. 1995;42:257–268. doi: 10.1111/j.1365-3083.1995.tb03652.x. [DOI] [PubMed] [Google Scholar]
  515. Szostecki C, Guldner HH, Will H. Autoantibodies against „nuclear dots“ in primary biliary cirrhosis. Semin Liver Dis. 1997;17:71–78. doi: 10.1055/s-2007-1007184. [DOI] [PubMed] [Google Scholar]
  516. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis. 2005;25:298–310. doi: 10.1055/s-2005-916321. [DOI] [PubMed] [Google Scholar]
  517. Reichlin M, Maddison PJ, Targoff I, Bunch T, Arnett F, Sharp G, Treadwell E, Tan EM. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol. 1984;4:40–44. doi: 10.1007/BF00915286. [DOI] [PubMed] [Google Scholar]
  518. Meyer W, Scheper T, Janssen A, Torkler S, Schlumberger W, Stöcker W (2007) EUROLINE Myositis Profile: A newly developed line immunoassay for the detection of myositis specific antibodies. In: Conrad K et al (eds) From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies. Pabst Science Publishers 5:612–613
  519. Hanke K, Brückner C, Dähnrich C, Huscher D, Becker M, Komorowski L, Meyer W, Jansen A, Backhaus M, Becker M, Kill A, Egerer K, Burmester G, Hiepe F, Schlumberger W, Riemekasten G. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther. 2009;11:22. doi: 10.1186/ar2614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  520. Van Der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, Es LA, Van Der Giessen M, Van Der Hem GK, The TH. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet. 1985;1:425–429. doi: 10.1016/S0140-6736(85)91147-X. [DOI] [PubMed] [Google Scholar]
  521. Savage COS, Winearls CG, Jones S, et al. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet. 1987;1:1389–1393. doi: 10.1016/S0140-6736(87)90591-5. [DOI] [PubMed] [Google Scholar]
  522. Sun J, Fass DN, Viss MA, Hummel AM, Tang H, Homburger HA, Specks U. A proportion of proteinase 3 (PR3)-specific antineutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide. Clin Exp Immunol. 1998;114:320–326. doi: 10.1046/j.1365-2249.1998.00730.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  523. Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA) Am J Clin Pathol. 1999;111:507–513. doi: 10.1093/ajcp/111.4.507. [DOI] [PubMed] [Google Scholar]
  524. Damoiseaux J, Buschtez M, Steller U, Zerbe B, Rosemann A, Fechner K, Schlumberger W, Cohen Tervaert JW, Stöcker W (2007) EUROPLUS ™ ANCA BIOCHIP Mosaic: MPO and PR3 antigen dots improve the detection of ANCA by indirect immunofluorescence. In: Conrad K et al (eds) From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies. Pabst Science Publishers 5:485–486
  525. Damoiseaux J, Steller U, Buschtez M, Vaessen M, Rosemann A, van Paassen P, Stöcker W, Fechner K, Cohen Tervaert JW. EUROPLUS ANCA BIOCHIP mosaic: PR3 and MPO antigen microdots improve the laboratory diagnostics of ANCA-associated vasculitis. J Immunol Methods. 2009;348:67–73. doi: 10.1016/j.jim.2009.07.001. [DOI] [PubMed] [Google Scholar]
  526. Damoiseaux J, Dähnrich C, Rosemann A, Probst C, Komorowski L, Stegeman CA, Egerer K, Hiepe F, van Paassen P, Stöcker W, Schlumberger W, Cohen Tervaert JW. A novel ELISA using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for ANCA-associated vasculitis. Ann Rheum Dis. 2009;68:228–233. doi: 10.1136/ard.2007.086579. [DOI] [PubMed] [Google Scholar]
  527. Strauss AJ, Seegal BC, Hsu KC, et al. Immunofluorescence demonstration of a muscle binding, complement-fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol Med. 1960;105:184–191. [Google Scholar]
  528. Steiner G, Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 2002;4(2):1–5. doi: 10.1186/ar551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  529. Elkon KB, Bonfa E, Weissbach H, Brot N. Antiribosomal antibodies in SLE, infection, and following deliberate immunization. Adv Exp Med Biol. 1994;347:81–92. doi: 10.1007/978-1-4615-2427-4_9. [DOI] [PubMed] [Google Scholar]
  530. Caponi L, Giordano A, Bartoloni EB, Gerli R. Detection of antiribosome antibodies: a long story of lights and shadows. Clin Exp Rheumatol. 2003;21:771–778. [PubMed] [Google Scholar]
  531. Gressner AM, Wool IG. The phosphorylation of liver ribosomal proteins in vivo. J Biol Chem. 1974;249:6917–6925. [PubMed] [Google Scholar]
  532. Després N, Boire G, Lopez-Longo FJ, Ménard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol. 1994;21:1027–1033. [PubMed] [Google Scholar]
  533. Vossenaar ER, Després N, Lapointe E, Van Der Heijden A, Lora M, Senshu T, van Venrooij WJ, Ménard HA. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004;6:R142–150. doi: 10.1186/ar1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  534. Ménard HA. Anti-CCP versus anti-Sa antibodies for the diagnosis of RA. Nat Clin Pract Rheumatol. 2007;3:76–77. doi: 10.1038/ncprheum0401. [DOI] [PubMed] [Google Scholar]
  535. Tan EM, Chan EKL, Sullivan KF, Rubin RL. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol. 1988;47:121–141. doi: 10.1016/0090-1229(88)90066-9. [DOI] [PubMed] [Google Scholar]
  536. Fritzler MJ. Autoantibodies in Scleroderma. The Journal of Dermatology. 1993;20:257–268. doi: 10.1111/j.1346-8138.1993.tb01389.x. [DOI] [PubMed] [Google Scholar]
  537. Hanke K, Dähnrich C, Brückner C, Huscher D, Becker M, Jansen A, Meyer W, Egerer K, Hiepe F, Burmester G, Schlumberger W, Riemekasten G. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther. 2009;11:28. doi: 10.1186/ar2622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  538. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259–264. doi: 10.1136/gut.51.2.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  539. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259–264. doi: 10.1136/gut.51.2.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  540. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet. 2000;355:1510–1515. doi: 10.1016/S0140-6736(00)02166-8. [DOI] [PubMed] [Google Scholar]
  541. Tan EM, Chan EKL, Sullivan KF, et al. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol. 1988;47:121–141. doi: 10.1016/0090-1229(88)90066-9. [DOI] [PubMed] [Google Scholar]
  542. MacSween RN, Goudie RB, Anderson JR, et al. Occurrence of antibody to salivary duct epithelium in Sjogren’s disease, rheumatoid arthritis, and other arthritides. A clinical and laboratory study. Ann Rheum Dis. 1967;26:402–411. doi: 10.1136/ard.26.5.402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  543. Andrade LE, Chan EK, Peebles CL, Tan EM. Two major autoantigen-antibody systems of the mitotic spindle apparatus. Arthritis Rheum. 1996;39:1643–1653. doi: 10.1002/art.1780391006. [DOI] [PubMed] [Google Scholar]
  544. Whitehead CM, Winkfein RJ, Fritzler MJ, Rattner JB. The spindle kinesin-like protein HsEg5 is an autoantigen in systemic lupus erythematosus. Arthritis Rheum. 1996;39:1635–1642. doi: 10.1002/art.1780391005. [DOI] [PubMed] [Google Scholar]
  545. Grypiotis P, Ruffatti A, Tonello M, Winzler C, Radu C, Zampieri S, Favaro M, Calligaro A, Todesco S. Clinical significance of fluoroscopic patterns specific for the mitotic spindle in patients with rheumatic diseases. Reumatismo. 2002;54:232–237. doi: 10.4081/reumatismo.2002.232. [DOI] [PubMed] [Google Scholar]
  546. Bonaci-Nikolic B, Andrejevic S, Bukilica M, Urosevic I, Nikolic M. Autoantibodies to mitotic apparatus: Association with other autoantibodies and their clinical significance. J Clin Immunol. 2006;26:438–446. doi: 10.1007/s10875-006-9038-y. [DOI] [PubMed] [Google Scholar]
  547. Mozo L, Gutiérrez C, Gómez J. Antibodies to mitotic spindle apparatus: Clinical significance of NuMA and HsEg5 autoantibodies. J Clin Immunol. 2008;28:285–290. doi: 10.1007/s10875-008-9170-y. [DOI] [PubMed] [Google Scholar]
  548. Tan EM, Chan EKL, Sullivan KF, Rubin RL. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol. 1988;47:121–141. doi: 10.1016/0090-1229(88)90066-9. [DOI] [PubMed] [Google Scholar]
  549. Boire G, Gendron M, Monast N, Bastin B, Ménard HA. Purification of antigenically intact Ro ribonucleoproteins; biochemical and immunological evidence that the 52-kDa protein is not a Ro protein. Clin exp Immunol. 1995;100:489–498. doi: 10.1111/j.1365-2249.1995.tb03728.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  550. Meyer W, Scheper T, Siegemund M, Takeuchi K, Schlumberger W, Stöcker W (2004) The SS-A/Ro60 kDa protein is sufficient for the detection of autoantibodies against SS-A. In: Conrad K et al (eds) From animal models to human genetics: Research on the induction and pathogenicity of autoantibodies. Pabst Science Publishers 4:525–526
  551. Gordon P, Khamashta MA, Rosenthal E, Simpson JM, Sharland G, Brucato A, Franceschini F, Bosschere K, Meheus L, Meroni PL, Hughes GR, Buyon J. Anti-52 kDa Ro, anti-60 kDa Ro, and anti- La antibody profiles in neonatal lupus. J Rheumatol. 2004;31:2480–2487. [PubMed] [Google Scholar]
  552. Anderson JR, Goudie RB, Gray K, et al. Immunological features of idiopathic Addison’s disease: an antibody to cells producing steroid hormones. Clin Exp Immunol. 1968;3:107–117. [PMC free article] [PubMed] [Google Scholar]
  553. Betterle C, Pra C, Mantero F, et al. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocrine Reviews. 2002;23:327–364. doi: 10.1210/er.23.3.327. [DOI] [PubMed] [Google Scholar]
  554. Seissler J, Schott M, Steinbrenner H, et al. Autoantibodies to adrenal cytochrome P450 antigens in isolated Addison’s disease and autoimmune polyendocrine syndrome type II. Exp Clin Endocrinol Diabetes. 1999;107:208–213. doi: 10.1055/s-0029-1212100. [DOI] [PubMed] [Google Scholar]
  555. Mueller-Eckhard C. Transfusionsmedizin. Berlin Heidelberg New York: Springer- Verlag; 1996. [Google Scholar]
  556. Gentile F, Conte M, Formisano S. Thyroglobulin as an autoantigen: What we can learn about immunopathogenicity from the correlation of antigenic properties with protein structure. Immunology. 2004;112:13–25. doi: 10.1111/j.1365-2567.2004.01861.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  557. Aarli JA, Stefansson K, Marton LS, et al. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol. 1990;82:284–288. doi: 10.1111/j.1365-2249.1990.tb05440.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  558. Romi F, Skeie GO, Aarli JA, et al. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol. 2000;247:369–375. doi: 10.1007/s004150050604. [DOI] [PubMed] [Google Scholar]
  559. Bernal F, Shams’ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, Honnorat J, Smitt P, Graus F. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology. 2003;60:230–234. doi: 10.1212/01.WNL.0000041495.87539.98. [DOI] [PubMed] [Google Scholar]
  560. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler CH, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–1140. doi: 10.1136/jnnp.2003.034447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  561. Orgiazzi J. Anti-TSH receptor antibodies in clinical practice. Endocrinol Metab Clin North Am. 2000;29:339–355. doi: 10.1016/S0889-8529(05)70135-3. [DOI] [PubMed] [Google Scholar]
  562. Smith B. Thyroid autoantibodies. Scand J Clin Lab Invest Suppl. 2001;61:45–52. doi: 10.1080/003655101753352040. [DOI] [PubMed] [Google Scholar]
  563. Saravanan P, Dayan CM. Thyroid autoantibodies. Endocrinol Metab Clin North Am. 2001;30:315–337. doi: 10.1016/S0889-8529(05)70189-4. [DOI] [PubMed] [Google Scholar]
  564. Tan EM, Chan EKL, Sullivan KF, et al. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol. 1988;47:121–141. doi: 10.1016/0090-1229(88)90066-9. [DOI] [PubMed] [Google Scholar]
  565. Scherbaum WA, Bottazzo GF. Autoantibodies to vasopressin cells in idiopathic diabetes insipidus: evidence for an autoimmune variant. Lancet. 1983;1:897–901. doi: 10.1016/S0140-6736(83)91328-4. [DOI] [PubMed] [Google Scholar]
  566. Pivonello R, Bellis A, Faggiano A, et al. Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. J Clin Endocrinol Metab. 2003;88:1629–1636. doi: 10.1210/jc.2002-020791. [DOI] [PubMed] [Google Scholar]
  567. Voltz R. Paraneoplastische neurologische Autoimmunerkrankungen. Nervenarzt. 2002;73:909–929. doi: 10.1007/s00115-002-1407-z. [DOI] [PubMed] [Google Scholar]
  568. Tan EM, Chan EKL, Sullivan KF, Rubin RL. Antinuclear antibodies (ANAs): Diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol. 1988;47:121–141. doi: 10.1016/0090-1229(88)90066-9. [DOI] [PubMed] [Google Scholar]
  569. Fritzler MJ. Autoantibodies in scleroderma. J Dermatol. 1993;20:68. doi: 10.1111/j.1346-8138.1993.tb01389.x. [DOI] [PubMed] [Google Scholar]
  570. Schlumberger W, Olbrich S, Müller-Kunert E, Stöcker W (1994) Autoantikörper-Diagnostik mit der Substratkombination: Humane Epithelzellen (HEp-2) und Primatenleber. Differenzierung der Antikörper durch Enzymimmuntests. Eigenverlag der EUROIMMUN AG, Lübeck, Deutschland
  571. Genth E, Mierau R. Diagnostische Bedeutung Sklerodermieund Myositis-assoziierter Autoantikörper. Z Rheumatol. 1995;54:39–49. [PubMed] [Google Scholar]
  572. Schlumberger W, Meyer W, Proost S, Dähnrich C, Müller-Kunert E, Sonnenberg K, Olbrich S, Stöcker W. The new EUROBLOT technology: Differentiation of Autoantibodies against cell nuclei. Eur J Clin Chem Clin Biochem. 1995;33:A68–A69. [Google Scholar]
  573. Suer W, Dähnrich C, Schlumberger W, Stöcker W. Autoantibodies in SLE but not in scleroderma react with protein-stripped nucleosomes. J Autoimmun. 2004;22:325–334. doi: 10.1016/j.jaut.2004.02.002. [DOI] [PubMed] [Google Scholar]
  574. Yamasaki Y, Narain S, Yoshida H, Hernandez L, Barker T, Hahn PC, Sobel ES, Segal MS, Richards HB, Chan EK, Reeves WH, Satoh M. Autoantibodies to RNA helicase A: A new serologic marker of early lupus. Arthritis Rheum. 2007;56:596–604. doi: 10.1002/art.22329. [DOI] [PubMed] [Google Scholar]
  575. Gavanescu I, Vazquez-Abad D, McCauley J, Senecal JL, Doxsey S. Centrosome proteins: a major class of autoantigens in scleroderma. J Clin Immunol. 1999;19:166–171. doi: 10.1023/A:1020551610319. [DOI] [PubMed] [Google Scholar]
  576. Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci. 1980;77:1627–1631. doi: 10.1073/pnas.77.3.1627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  577. Meurer M, Scharf A, Luderschmidt C, Braun-Falco O. Zentromerantikörper und Antikörper gegen Scl-70-Nucleoprotein bei progressiver systemischer Sklerodermie: Diagnostische und prognostische Bedeutung. Dtsch Med Wschr. 1985;110:8–14. doi: 10.1055/s-2008-1068765. [DOI] [PubMed] [Google Scholar]
  578. Hanke K, Uibel S, Brückner C, Dähnrich C, Egerer K, Hiepe F, Schlumberger W, Riemekasten G (2007) Antibodies to CENP-B antigen identify a subgroup of systemic sclerosis patients presenting more frequently sicca syndrome and less frequently lung fibrosis, cardiac and vascular involvement – analysis of the Charité SSc cohort.
  579. In: Conrad K et al (eds) From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies. Pabst Science Publishers 5:477–478
  580. Wenzlau JM, Juhl K, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton C. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA. 2007;104:17040–17045. doi: 10.1073/pnas.0705894104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  581. Wenzlau JM, Hutton JC, Davidson HW. New antigenic targets in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2008;15:315–320. doi: 10.1097/MED.0b013e328308192b. [DOI] [PubMed] [Google Scholar]
  582. Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, Walters J, Eisenbarth GS, Davidson HW, Hutton JC. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes. 2008;57:2693–2697. doi: 10.2337/db08-0522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  583. Leung PS, Iwayama T, Prindiville T, et al. Use of designer recombinant mitochondrial antigens in the diagnosis of primary biliary cirrhosis. Hepatology. 1992;15:367–372. doi: 10.1002/hep.1840150302. [DOI] [PubMed] [Google Scholar]
  584. Szostecki C, Will H, Netter HJ, et al. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand J Immunol. 1992;36:555–564. doi: 10.1111/j.1365-3083.1992.tb03224.x. [DOI] [PubMed] [Google Scholar]
  585. Sternsdorf T, Guldner HH, Szostecki C, et al. Two nuclear dotassociated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol. 1995;42:257–268. doi: 10.1111/j.1365-3083.1995.tb03652.x. [DOI] [PubMed] [Google Scholar]
  586. Wesierska-Gadek J, Hohenauer H, Hitchman E, et al. Antigp210 antibodies in sera of patients with primary biliary cirrhosis. Identification of a 64 kD fragment of gp210 as a major epitope. 1996;7:167–174. [PubMed] [Google Scholar]
  587. Wesierska-Gadek J, Hohenauer H, Hitchman E, et al. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology. 1996;110:840–847. doi: 10.1053/gast.1996.v110.pm8608894. [DOI] [PubMed] [Google Scholar]
  588. Szostecki C, Guldner HH, Will H. Autoantibodies against „nuclear dots“ in primary biliary cirrhosis. Semin Liver Dis. 1997;17:71–78. doi: 10.1055/s-2007-1007184. [DOI] [PubMed] [Google Scholar]
  589. Zuchner D, Sternsdorf T, Szostecki C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology. 1997;26:1123–1130. doi: 10.1002/hep.510260506. [DOI] [PubMed] [Google Scholar]
  590. Lapierre P, Hajoui O, Homberg JC, et al. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116:643–649. doi: 10.1016/S0016-5085(99)70186-1. [DOI] [PubMed] [Google Scholar]
  591. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet. 2000;355:1510–1515. doi: 10.1016/S0140-6736(00)02166-8. [DOI] [PubMed] [Google Scholar]
  592. Invernizzi PM, Podda PM, Battezzati A, et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol. 2001;34:366–372. doi: 10.1016/S0168-8278(00)00040-4. [DOI] [PubMed] [Google Scholar]
  593. Invernizzi P, Selmi C, Ranftler C, et al. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis. 2005;25:298–310. doi: 10.1055/s-2005-916321. [DOI] [PubMed] [Google Scholar]
  594. Salama A, Gaedicke G. Autoimmunhämolytische Anämien. In: Gadner H, Gaedicke G, Niemeyer C, Ritter J, editors. Pädiatrische Hämatologie: Anämien und Hämoglobinopathen. Berlin Heidelberg: Springer- Verlag; 2006. pp. 147–154. [Google Scholar]
  595. Eckstein R. Immunhämatologie und Transfusionsmedizin. 5. Stuttgart: Gustav Fischer; 2005. [Google Scholar]
  596. Murphy K, Travers P, Walport M (2011) Janeway’s Immunobiology, 8th ed. Taylor & Francis Ltd
  597. Nakamura RM. Concepts of Autoimmunity and Autoimmune Diseases. In: Nakamura RM, Keren DF, Bylund DJ, editors. Clinical and Laboratory Evaluation of Human Autoimmune Diseases. Chicago: ASCP Press; 2001. pp. 13–35. [Google Scholar]
  598. Nakamura RM. Concepts of Autoimmunity and Autoimmune Diseases. In: Nakamura RM, Keren DF, Bylund DJ, editors. Clinical and Laboratory Evaluation of Human Autoimmune Diseases. Chicago: ASCP Press; 2001. pp. 13–35. [Google Scholar]
  599. Nakamura RM. Concepts of Autoimmunity and Autoimmune Diseases. In: Nakamura RM, Keren DF, Bylund DJ, editors. Clinical and Laboratory Evaluation of Human Autoimmune Diseases. Chicago: ASCP Press; 2001. pp. 13–35. [Google Scholar]
  600. Murphy K, Travers P, Walport M (2011) Janeway’s Immunobiology, 8th ed. Taylor & Francis
  601. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17:393–398. doi: 10.1038/ng1297-393. [DOI] [PubMed] [Google Scholar]
  602. Nakamura RM. Concepts of Autoimmunity and Autoimmune Diseases. In: Nakamura RM, Keren DF, Bylund DJ, editors. Clinical and Laboratory Evaluation of Human Autoimmune Diseases. Chicago: ASCP Press; 2001. pp. 13–35. [Google Scholar]
  603. Mueller-Eckhardt C, Kiefel V, editors. Transfusionsmedizin: Grundlagen – Therapie – Methodik. 3. Berlin Heidelberg New York: Springer-Verlag; 2004. [Google Scholar]
  604. Eckstein R. Immunhämatologie und Transfusionsmedizin. 5. Stuttgart: Gustav Fischer; 2005. [Google Scholar]
  605. Bundesärztekammer (2005) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Aufgestellt gemäß Transfusionsgesetz von der Bundesärztekammer im Einvernehmen mit dem Paul-Ehrlich-Institut, Gesamtnovelle 2005, Deutscher Ärzteverlag, Köln
  606. Lehman DC (2007) Biochemical Identification of Gram- Negative Bacteria. In: Mahon CR, Lehman DC, Manuselis G (eds) Textbook of Diagnostic Microbiology. 3. Aufl. Saunders Elsevier, pp 226–232
  607. Kingston HM, Kingston ML. Nomenclature in laboratory robotics and automation. IUPAC recommendations 1994. Pure & Appl Chem. 1994;66:609–630. doi: 10.1351/pac199466030609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  608. Haeckel R, et al. Rationalisierung quantitativer Analysenverfahren. In: Greiling H, Gressner AM, et al., editors. Lehrbuch der Klinischen Chemie und Pathobiochemie. Stuttgart New York: Schattauer Verlag; 1995. [Google Scholar]
  609. Brown TA (Hrsg) Moderne Genetik. 2. Aufl. Spektrum Akademischer Verlag, Heidelberg-Berlin, S 19
  610. Berzowsky JA, Epstein SL, Berkower IJ. Antigen-antibody interactions and monoclonal antibodies. In: Paul WE, editor. Fundamental Immunology. 2nd. New York: Raven Press; 1989. pp. 315–356. [Google Scholar]
  611. Klein J. Antigen-antibody interactions. In: Klein J, Horejsi V, editors. Immunology. Cambridge MA: Blackwell Scientific; 1990. pp. 294–310. [Google Scholar]
  612. Kaufmann SHE. Antikörper und ihre Antigene. In: Hahn H, Falke D, Kaufmann SHE, Ullmann U, editors. Medizinische Mikrobiologie und Infektiologie. 5. Heidelberg Berlin New York: Springer-Verlag; 2004. pp. 61–77. [Google Scholar]
  613. Levett PN, Sonnenberg K, Sidaway F, Shead S, Niedrig M, Steinhagen K, Horsman GB, Drebot MA. Use of IgG avidity assays for differentiation of primary from previous infections with West Nile virus. J Clin Microbiol. 2005;43:5873–5875. doi: 10.1128/JCM.43.12.5873-5875.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  614. Chan KH, Sonnenberg K, Niedrig M, Lam SY, Pang CM, Chan KM, Ma SK, Seto WH, Peiris JSM. Use of antibody avidity assays for diagnosis of severe acute respiratory syndrome coronavirus infection. Clin Vaccine Immunol. 2007;14:1433–1436. doi: 10.1128/CVI.00056-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  615. Simoni M, Bakker E, Krausz C. EAA/EMQN Best Practice Guidelines for Molecular Diagnosis of Y-Chromosomal Microdeletions. State of the Art 2004. Int J Androl. 2004;27:240–249. doi: 10.1111/j.1365-2605.2004.00495.x. [DOI] [PubMed] [Google Scholar]
  616. Raicu F, Popa L, Apostol P, et al. Screening for Microdeletions in Human Y Chromosome – AZF Candidate Genes and Male Infertility. J Cell Mol Med. 2003;7:43–48. doi: 10.1111/j.1582-4934.2003.tb00201.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Lexikon der Medizinischen Laboratoriumsdiagnostik are provided here courtesy of Nature Publishing Group

RESOURCES